Application of Molecular Ultrasound for Imaging Integrin Expression
暂无分享,去创建一个
[1] E. Chamberlain. Coronary Thrombosis , 1957, The British journal of clinical practice.
[2] J. Woodruff,et al. Lymphocyte homing into lymph nodes: in vitro demonstration of the selective affinity of recirculating lymphocytes for high-endothelial venules , 1976, The Journal of experimental medicine.
[3] R. Flower,et al. Indocyanine green dye fluorescence and infrared absorption choroidal angiography performed simultaneously with fluorescein angiography. , 1976, The Johns Hopkins medical journal.
[4] P. Agin,et al. Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins. , 1977, The Journal of clinical investigation.
[5] K. Ericson,et al. DETECTION OF ATHEROSCLEROTIC PLAQUES IN CAROTID ARTERIES BY THE USE OF 123I-FIBRINOGEN , 1978, The Lancet.
[6] R. Doolittle,et al. The amino acid sequence of the alpha-chain of human fibrinogen. , 1979, Nature.
[7] S. Timmons,et al. gamma and alpha chains of human fibrinogen possess sites reactive with human platelet receptors. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[8] J. Laufer. [Precancerous lesions of the oral mucosa]. , 1982, Actualites odonto-stomatologiques.
[9] R. Gaylord. unpublished results , 1985 .
[10] Michael Loran Dustin,et al. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. , 1986, Journal of immunology.
[11] D. Mccormick. Sequence the Human Genome , 1986, Bio/Technology.
[12] Richard O. Hynes,et al. Integrins: A family of cell surface receptors , 1987, Cell.
[13] J. Strominger,et al. The very late antigen family of heterodimers is part of a superfamily of molecules involved in adhesion and embryogenesis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[14] E Ruoslahti,et al. New perspectives in cell adhesion: RGD and integrins. , 1987, Science.
[15] D. Cheresh. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[16] T. Springer,et al. Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. , 1987, Annual review of medicine.
[17] D. Cheresh,et al. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. , 1987, The Journal of biological chemistry.
[18] W Börner,et al. 99Tcm hexamethylpropyleneamineoxime (HMPAO) as a platelet label: evaluation of labelling parameters and first in vivo results. , 1988, Nuclear medicine communications.
[19] A. Fischman,et al. Imaging Human Atherosclerosis with 99mTc‐labeled Low Density Lipoproteins , 1988, Arteriosclerosis.
[20] R Weissleder,et al. Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging. , 1988, Radiology.
[21] J. Bigby. Harrison's Principles of Internal Medicine , 1988 .
[22] I. Weissman,et al. Identification of a murine Peyer's patch--specific lymphocyte homing receptor as an integrin molecule with an alpha chain homologous to human VLA-4 alpha. , 1989, Cell.
[23] R. Ahmadi,et al. Indium-111-labeled platelet scintigraphy in carotid atherosclerosis. , 1989, Stroke.
[24] L. Knight,et al. Radiopharmaceuticals for thrombus detection. , 1990, Seminars in nuclear medicine.
[25] R. Pitti,et al. Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[26] M J Davies,et al. A macro and micro view of coronary vascular insult in ischemic heart disease. , 1990, Circulation.
[27] R. Clark. Fibronectin matrix deposition and fibronectin receptor expression in healing and normal skin. , 1990, The Journal of investigative dermatology.
[28] D. Elder,et al. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. , 1990, Cancer research.
[29] S. Vallabhajosula,et al. Noninvasive imaging of 99mtechnetium-labeled low density lipoprotein uptake by tendon xanthomas in hypercholesterolemic patients. , 1990, Arteriosclerosis.
[30] David R. Phillips,et al. GPIIb-IIIa: The responsive integrin , 1991, Cell.
[31] R. Timpl,et al. Arg‐Gly‐Asp constrained within cyclic pentapoptides Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 , 1991, FEBS letters.
[32] K. Chan,et al. Cyclic RGD peptide analogues as antiplatelet antithrombotics. , 1992, Journal of medicinal chemistry.
[33] Richard O. Hynes,et al. Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.
[34] R. Timpl,et al. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. , 1992, European journal of biochemistry.
[35] V. Fuster,et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). , 1992, The New England journal of medicine.
[36] M. Cerqueira,et al. Noninvasive Arterial Thrombus Imaging With 99mTc Monoclonal Antifibrin Antibody , 1992, Circulation.
[37] R J Lynch,et al. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. , 1992, Journal of medicinal chemistry.
[38] R. Timpl,et al. Dynamic Forcing, a Method for Evaluating Activity and Selectivity Profiles of RGD (Arg‐Gly‐Asp) Peptides , 1992 .
[39] D. Cheresh,et al. Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. , 1992, The Journal of clinical investigation.
[40] M. Di Loreto,et al. Immunodetection of human atherosclerotic plaque with 125I-labeled monoclonal antifibrin antibodies. , 1993, Atherosclerosis.
[41] M. Arnaout,et al. A novel divalent cation-binding site in the a domain of the β 2 integrin CR3 (CD11b/CD18) is essential for ligand binding , 1993, Cell.
[42] R. Harlow. The structure of water as organized in an RGD peptide crystal at -80.degree.C , 1993 .
[43] V. Garsky,et al. Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein. , 1993, Endocrinology.
[44] D. Sheppard,et al. Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[45] R. Lees,et al. External Imaging of Atherosclerosis in Rabbits Using an 123I‐Labeled Synthetic Peptide Fragment , 1993, Journal of clinical pharmacology.
[46] S. Kennel,et al. Expression of β1, β3, β4, and β5 Integrins by Human Lung Carcinoma Cells of Different Histotypes , 1994 .
[47] D. Cheresh,et al. Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.
[48] D. Craik,et al. A common structural motif incorporating a cystine knot and a triple‐stranded β‐sheet in toxic and inhibitory polypeptides , 1994, Protein science : a publication of the Protein Society.
[49] T. Springer. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm , 1994, Cell.
[50] B. Engelhardt,et al. Evidence for involvement of ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in experimental autoimmune encephalomyelitis in the central nervous system in the SJL/J mouse. , 1994, The American journal of pathology.
[51] M M Haglund,et al. Enhanced optical imaging of rat gliomas and tumor margins. , 1994, Neurosurgery.
[52] S. Horwitz. Taxol (paclitaxel): mechanisms of action. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[53] R. Pedersen,et al. Deletion of beta 1 integrins in mice results in inner cell mass failure and peri-implantation lethality. , 1995, Genes & development.
[54] J. Folkman. Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.
[55] C. Heldin,et al. Platelet‐derived growth factor in human glioma , 1995, Glia.
[56] M. Horton. Interactions of connective tissue cells with the extracellular matrix. , 1995, Bone.
[57] P. Bornstein,et al. Diversity of Function Is Inherent in Matricellular Proteins: an Appraisal of Thrombospondin I , 1995 .
[58] M. Chalfie. GREEN FLUORESCENT PROTEIN , 1995, Photochemistry and photobiology.
[59] R. Liddington,et al. Crystal structure of the A domain from the a subunit of integrin CR3 (CD11 b/CD18) , 1995, Cell.
[60] M. Ginsberg,et al. The Conserved Membrane-proximal Region of an Integrin Cytoplasmic Domain Specifies Ligand Binding Affinity (*) , 1995, The Journal of Biological Chemistry.
[61] S. Somkuti. Epidermal growth factor and human uterine receptivity: regulation of the ?v?3 integrin vitronectin receptor , 1995 .
[62] M J Davies,et al. Acute coronary thrombosis--the role of plaque disruption and its initiation and prevention. , 1995, European heart journal.
[63] K. Aldape,et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. , 1995, Journal of cell science.
[64] D. Creamer,et al. Altered vascular endothelium integrin expression in psoriasis. , 1995, The American journal of pathology.
[65] M. Salvatore,et al. Detecting deep venous thrombosis with technetium-99m-labeled synthetic peptide P280. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[66] D. Cheresh,et al. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. , 1995, Journal of cell science.
[67] D. Cheresh,et al. An antagonist of integrin αvβ3 prevents maturation of blood vessels during embryonic neovascularization , 1995 .
[68] D. Cheresh,et al. Definition of two angiogenic pathways by distinct alpha v integrins. , 1995, Science.
[69] R. Hynes,et al. Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. , 1995, Development.
[70] J. Stone,et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity , 1995, Nature Medicine.
[71] F. Sarkar,et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. , 1995, The Journal of clinical investigation.
[72] V. Fuster,et al. T2-weighted contrast for NMR characterization of human atherosclerosis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[73] U. Kralisz. [Platelet collagen receptors]. , 1995, Postepy biochemii.
[74] R. Liddington,et al. Two conformations of the integrin A-domain (I-domain): a pathway for activation? , 1995, Structure.
[75] R. Isberg,et al. The mechanism of phagocytic uptake promoted by invasin-integrin interaction. , 1995, Trends in cell biology.
[76] David A. Cheresh,et al. Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.
[77] R Pasqualini,et al. A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins , 1995, The Journal of cell biology.
[78] L. Penland,et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.
[79] L. Picker,et al. Lymphocyte Homing and Homeostasis , 1996, Science.
[80] C. Mackay,et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. , 1996, Gastroenterology.
[81] J. Tcheng. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. , 1996, The American journal of cardiology.
[82] 森脇 博. Functional and anatomic evaluation of carotid atherothrombosis : a combined study of indium 111 platelet scintigraphy and B-mode ultrasonography , 1996 .
[83] M. Ginsberg,et al. Trans-dominant inhibition of integrin function. , 1996, Molecular biology of the cell.
[84] W. DeGrado,et al. Type II‘ to Type I β-Turn Swap Changes Specificity for Integrins , 1996 .
[85] T. Harris,et al. Tc-99m-labeled fibrinogen receptor antagonists: design and synthesis of cyclic RGD peptides for the detection of thrombi , 1996 .
[86] M. Horton,et al. Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. , 1996, Endocrinology.
[87] P. Lu,et al. BIODISTRIBUTION AND AUTORADIOGRAPHIC LOCALIZATION OF I‐125-LABELED SYNTHETIC PEPTIDE IN AORTIC ATHEROSCLEROSIS IN CHOLESTEROL‐FED RABBITS , 1996, American journal of therapeutics.
[88] Zaverio M. Ruggeri,et al. Role of 3 Integrins in Melanoma Cell Adhesion to Activated Platelets under Flow (*) , 1996, The Journal of Biological Chemistry.
[89] V. O’Brien,et al. Expression of the integrin alpha 5 subunit in HT29 colon carcinoma cells suppresses apoptosis triggered by serum deprivation. , 1996, Experimental cell research.
[90] L. Knight,et al. Thrombus imaging with a technetium-99m-labeled activated platelet receptor-binding peptide. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[91] J. Moake,et al. Platelets and shear stress. , 1996, Blood.
[92] Shuang Liu,et al. Biological evaluation of 99mTc-labeled cyclic glycoprotein IIb/IIIa receptor antagonists in the canine arteriovenous shunt and deep vein thrombosis models: effects of chelators on biological properties of [99mTc]chelator-peptide conjugates. , 1996, Bioconjugate chemistry.
[93] M. Rajopadhye,et al. Labeling cyclic glycoprotein IIb/IIIa receptor antagonists with 99mTc by the preformed chelate approach: effects of chelators on properties of [99mTc]chelator-peptide conjugates. , 1996, Bioconjugate chemistry.
[94] R. Virmani,et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. , 1996, Circulation.
[95] J. Barrett,et al. Labeling a hydrazino nicotinamide-modified cyclic IIb/IIIa receptor antagonist with 99mTc using aminocarboxylates as coligands. , 1996, Bioconjugate chemistry.
[96] G. Ronga,et al. Preparation and biodistribution of 99m technetium labelled oxidized LDL in man. , 1996, Atherosclerosis.
[97] A. Rademaker,et al. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[98] S. Cherry,et al. Simultaneous PET and MR imaging , 1997, Physics in medicine and biology.
[99] A. Giannis,et al. Integrin Antagonists and Other Low Molecular Weight Compounds as Inhibitors of Angiogenesis: New Drugs in Cancer Therapy , 1997 .
[100] Erkki Ruoslahti,et al. αv Integrins as receptors for tumor targeting by circulating ligands , 1997, Nature Biotechnology.
[101] L. Jennings,et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. , 1997, Circulation.
[102] N. Rao,et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[103] Luzhe Sun,et al. Role of α5β1 integrin in determining malignant properties of colon carcinoma cells , 1997 .
[104] M. Crescenzi,et al. α6β4 and α6β1 Integrins Associate with ErbB-2 in Human Carcinoma Cell Lines , 1997 .
[105] J. Barrett,et al. New and versatile ternary ligand system for technetium radiopharmaceuticals: water soluble phosphines and tricine as coligands in labeling a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with 99mTc. , 1997, Bioconjugate chemistry.
[106] F. Watt,et al. Changes in the expression of αv integrins in oral squamous cell carcinomas , 1997 .
[107] J. Lazewatsky,et al. Biological evaluation of thrombus imaging agents utilizing water soluble phosphines and tricine as coligands when used to label a hydrazinonicotinamide-modified cyclic glycoprotein IIb/IIIa receptor antagonist with 99mTc. , 1997, Bioconjugate chemistry.
[108] R. Harrington,et al. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. , 1997, Circulation.
[109] Horst Kessler,et al. Stereoisomeric Peptide Libraries and Peptidomimetics for Designing Selective Inhibitors of the αvβ3 Integrin for a New Cancer Therapy , 1997 .
[110] Stgrp Capture,et al. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.
[111] W. Risau,et al. Mechanisms of angiogenesis , 1997, Nature.
[112] K M Kessler,et al. Frequency of sudden cardiac death and profiles of risk. , 1997, The American journal of cardiology.
[113] Leslie M Shaw,et al. Activation of Phosphoinositide 3-OH Kinase by the α6β4 Integrin Promotes Carcinoma Invasion , 1997, Cell.
[114] R. Nelson,et al. Superparamagnetic iron oxide particles (SH U 555 A): evaluation of efficacy in three doses for hepatic MR imaging. , 1998, Radiology.
[115] I. Holt,et al. Integrin subunit β3 plays a crucial role in the movement of osteoclasts from the periosteum to the bone surface , 1998, Journal of cellular physiology.
[116] J. M. Scholtz,et al. Osteopontin is a ligand for the alpha4beta1 integrin. , 1998, Journal of cell science.
[117] R. Jordan,et al. Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and αvβ3 Integrins , 1998 .
[118] C. Barbas,et al. A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[119] M. Roe,et al. The EPILOG trial. Abciximab prevents ischemic complications during angioplasty. Evaluation in PTCA to improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade. , 1998, Cleveland Clinic journal of medicine.
[120] C. Leu,et al. The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. , 1998, Endocrinology.
[121] G. Rodan,et al. Echistatin inhibits the migration of murine prefusion osteoclasts and the formation of multinucleated osteoclast-like cells. , 1998, Endocrinology.
[122] A. Harris,et al. A novel ternary ligand system for 99mTc-labeling of hydrazino nicotinamide-modified biologically active molecules using imine-N-containing heterocycles as coligands. , 1998, Bioconjugate chemistry.
[123] M. Valle,et al. Power Doppler sonography: clinical applications. , 1998, European journal of radiology.
[124] R Brancato,et al. Fluorescein and indocyanine green angiography in vascular chorioretinal diseases. , 1998, Seminars in ophthalmology.
[125] D. Sheppard,et al. The integrin α v β 6 is critical for keratinocyte migration on both its known ligand , fibronectin , and on vitronectin , 1998 .
[126] A. Epenetos,et al. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide , 1998, European Journal of Nuclear Medicine.
[127] David A. Cheresh,et al. Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging , 1998, Nature Medicine.
[128] S. Mousa. MECHANISMS OF ANGIOGENESIS IN VASCULAR DISORDERS : POTENTIAL THERAPEUTIC TARGETS , 1998 .
[129] Reinhold Förster,et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.
[130] R. Hynes,et al. Extensive Vasculogenesis, Angiogenesis, and Organogenesis Precede Lethality in Mice Lacking All αv Integrins , 1998, Cell.
[131] J. Humm,et al. Radioimmunotherapy with alpha-emitting nuclides , 1998, European Journal of Nuclear Medicine.
[132] E. Ruoslahti,et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.
[133] George M Whitesides,et al. Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. , 1998, Angewandte Chemie.
[134] S. Mousa,et al. Novel technetium‐99m‐labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis , 1998, Coronary artery disease.
[135] C. Leu,et al. Histomorphometric evidence for echistatin inhibition of bone resorption in mice with secondary hyperparathyroidism. , 1998, Endocrinology.
[136] R. Klemke,et al. Integrin αvβ3 Requirement for Sustained Mitogen-activated Protein Kinase Activity during Angiogenesis , 1998, The Journal of cell biology.
[137] N. Kleiman,et al. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? , 1999, Circulation.
[138] Sonia S Anand,et al. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. , 1999, JAMA.
[139] D. Cheresh,et al. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. , 1999, The Journal of clinical investigation.
[140] E. Bramucci,et al. Antithrombotic therapy of unstable angina and non-Q-wave myocardial infarction. , 1999, International journal of cardiology.
[141] R Weissleder,et al. Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. , 1999, Bioconjugate chemistry.
[142] P. Hahnfeldt,et al. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.
[143] J. Witztum,et al. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo , 1999, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
[144] R. Carretta,et al. Optimizing images of acute deep-vein thrombosis using technetium-99m-apcitide. , 1999, Journal of nuclear medicine technology.
[145] G. Mizejewski. Role of Integrins in Cancer: Survey of Expression Patterns (44435) , 1999 .
[146] M. Welch,et al. Radiometal-labeled agents (non-technetium) for diagnostic imaging. , 1999, Chemical reviews.
[147] G. Soulez,et al. Comparison of early and delayed scintigraphy with 99mTc-apcitide and correlation with contrast-enhanced venography in detection of acute deep vein thrombosis. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[148] E. Lane,et al. Binding of Integrin α6β4 to Plectin Prevents Plectin Association with F-Actin but Does Not Interfere with Intermediate Filament Binding , 1999, The Journal of cell biology.
[149] Shuang Liu,et al. 99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals. , 1999, Chemical reviews.
[150] J. Munger. The integrin αvβ6 binds and activates latent TGFβ1 : A mechanism for regulating pulmonary inflammation and fibrosis , 1999 .
[151] R. Hynes,et al. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. , 1999, The Journal of clinical investigation.
[152] R. Jordan,et al. Readministration of abciximab: interim report of the ReoPro readministration registry. , 1999, American heart journal.
[153] M. Koller,et al. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS , 1999, Neurology.
[154] Horst Kessler,et al. Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting , 1999 .
[155] R. Hynes,et al. The Talin Head Domain Binds to Integrin β Subunit Cytoplasmic Tails and Regulates Integrin Activation* , 1999, The Journal of Biological Chemistry.
[156] L. Steinman,et al. The Immunobiology of Multiple Sclerosis: An Autoimmune Disease of the Central Nervous System , 1999, Neurobiology of Disease.
[157] M. Cerqueira,et al. Current status of radionuclide tracer imaging of thrombi and atheroma. , 1999, Seminars in nuclear medicine.
[158] S. Jurisson,et al. Potential technetium small molecule radiopharmaceuticals. , 1999, Chemical reviews.
[159] J. S. Reynolds,et al. Imaging of Spontaneous Canine Mammary Tumors Using Fluorescent Contrast Agents , 1999, Photochemistry and photobiology.
[160] K. Wennerberg,et al. β1 integrin promotes but is not essential for metastasis of ras-myc transformed fibroblasts , 1999, Oncogene.
[161] D. Hanahan,et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.
[162] Horst Kessler,et al. N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists , 1999 .
[163] L. Xue,et al. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. , 1999, Cancer biotherapy & radiopharmaceuticals.
[164] L. Zardi,et al. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. , 1999, Cancer research.
[165] P. Nurden,et al. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport. , 1999, Blood.
[166] H. Larjava,et al. Different integrins mediate cell spreading, haptotaxis and lateral migration of HaCaT keratinocytes on fibronectin. , 1999, Cell adhesion and communication.
[167] A. Harris,et al. 99mTc-labeling of hydrazones of a hydrazinonicotinamide conjugated cyclic peptide. , 1999, Bioconjugate chemistry.
[168] J. Barrett,et al. RP593, a 99mTc-labeled αvβ3/αvβ5 antagonist, rapidly detects spontaneous tumors in mice and dogs , 2000 .
[169] B. Bernard,et al. Evaluation of a radiolabeled cyclic DTPA-RGD analog for tumor imaging and radionuclide therapy , 2000 .
[170] The Esprit investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial , 2000, The Lancet.
[171] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[172] A. De Arcangelis,et al. Integrin and ECM functions: roles in vertebrate development. , 2000, Trends in genetics : TIG.
[173] R. Fässler,et al. Altered synthesis of laminin 1 and absence of basement membrane component deposition in (beta)1 integrin-deficient embryoid bodies. , 2000, Journal of cell science.
[174] N. Koshikawa,et al. Trypsin Stimulates Integrin α5β1-dependent Adhesion to Fibronectin and Proliferation of Human Gastric Carcinoma Cells through Activation of Proteinase-activated Receptor-2* , 2000, The Journal of Biological Chemistry.
[175] K. Arihiro,et al. Significance of α9β1 and αvβ6 integrin expression in breast carcinoma , 2000 .
[176] Semi Kim,et al. Regulation of Integrin αvβ3-mediated Endothelial Cell Migration and Angiogenesis by Integrin α5β1 and Protein Kinase A* , 2000, The Journal of Biological Chemistry.
[177] Robert V Farese,et al. Normal Development, Wound Healing, and Adenovirus Susceptibility in β5-Deficient Mice , 2000, Molecular and Cellular Biology.
[178] B. Curry,et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. , 2000, Cancer research.
[179] C. Botta,et al. Integrin function and regulation in development. , 2000, The International journal of developmental biology.
[180] D. Milenic. Radioimmunotherapy: designer molecules to potentiate effective therapy. , 2000, Seminars in radiation oncology.
[181] D. Waters,et al. Identification of coronary thrombus with a IIb/IIIa platelet inhibitor radiopharmaceutical, technetium-99m DMP-444: A canine model. , 2000, Circulation.
[182] Paul Kinahan,et al. A combined PET/CT scanner for clinical oncology. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[183] W. Oyen,et al. Scintigraphic detection of acute experimental endocarditis with the technetium-99m labelled glycoprotein IIb/IIIa receptor antagonist DMP444 , 2000, European Journal of Nuclear Medicine.
[184] W. Frishman,et al. Serotonin and the heart , 2000, Annals of medicine.
[185] Semi Kim,et al. Regulation of Angiogenesis in Vivo by Ligation of Integrin α5β1 with the Central Cell-Binding Domain of Fibronectin , 2000 .
[186] P. Carmeliet. Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.
[187] Robert V Farese,et al. Fatal Bilateral Chylothorax in Mice Lacking the Integrin α9β1 , 2000, Molecular and Cellular Biology.
[188] A. Gill,et al. A Small-Molecule, Tight-binding Inhibitor of the Integrin α4β1 Blocks Antigen-induced Airway Responses and Inflammation in Experimental Asthma in Sheep , 2000 .
[189] N. Kohno,et al. Significance of Integrin α5 Gene Expression as a Prognostic Factor in Node-negative Non-Small Cell Lung Cancer , 2000 .
[190] A. Metspalu,et al. Arrayed primer extension: solid-phase four-color DNA resequencing and mutation detection technology. , 2000, Genetic testing.
[191] R. Willette,et al. Identification and in vivo efficacy of small-molecule antagonists of integrin αvβ3 (the vitronectin receptor) , 2000 .
[192] E P Krenning,et al. Peptide receptor imaging and therapy. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[193] W. Oyen,et al. Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals. , 2000, Seminars in nuclear medicine.
[194] J. Witztum,et al. In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[195] H. Larjava,et al. Immunolocalization of Tenascin-C, α9 Integrin Subunit, and αvβ6 Integrin During Wound Healing in Human Oral Mucosa , 2000 .
[196] O. Platt,et al. Sickle cell anemia as an inflammatory disease. , 2000, The Journal of clinical investigation.
[197] R. Taillefer,et al. Acute thromboscintigraphy with (99m)Tc-apcitide: results of the phase 3 multicenter clinical trial comparing 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. Multicenter Trial Investigators. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[198] J. Barrett,et al. Detection of deep venous thrombosis by DMP 444, a platelet IIb/IIIa antagonist: A preliminary report , 2000, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.
[199] F. Mitjans,et al. In vivo therapy of malignant melanoma by means of antagonists of αv integrins , 2000 .
[200] K. Kurachi,et al. the PHSCN Sequence in Prostate Carcinoma Anti-invasive , Antitumorigenic , and Antimetastatic Activities of Updated Version , 2000 .
[201] R. Taillefer,et al. Results of the Phase 3 Multicenter Clinical Trial Comparing 99mTc-Apcitide Scintigraphy with Contrast Venography for Imaging Acute DVT , 2000 .
[202] R. Hynes,et al. Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts. , 2000, The Journal of clinical investigation.
[203] Richard W. Farndale,et al. Structural Basis of Collagen Recognition by Integrin α2β1 , 2000, Cell.
[204] V. Ntziachristos,et al. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[205] A. Pozzi,et al. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[206] A. Eberle,et al. Receptor targeting for tumor localisation and therapy with radiopeptides. , 2000, Current medicinal chemistry.
[207] R Weissleder,et al. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. , 2000, Cancer research.
[208] A. Sonnenberg,et al. The Tetraspan Molecule Cd151, a Novel Constituent of Hemidesmosomes, Associates with the Integrin α6β4 and May Regulate the Spatial Organization of Hemidesmosomes , 2000, The Journal of cell biology.
[209] H. Ishii,et al. Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. , 2000, The Journal of pharmacology and experimental therapeutics.
[210] R. Timpl,et al. Skin and hair follicle integrity is crucially dependent on β1 integrin expression on keratinocytes , 2000, The EMBO journal.
[211] T. N. Campbell,et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[212] C. Ruhrberg,et al. Endogenous inhibitors of angiogenesis. , 2001, Journal of cell science.
[213] B. Geiger,et al. Transmembrane crosstalk between the extracellular matrix--cytoskeleton crosstalk. , 2001, Nature reviews. Molecular cell biology.
[214] A. Schubiger,et al. Copper-67 as a therapeutic nuclide for radioimmunotherapy , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[215] Shuang Liu,et al. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. , 2001, Bioconjugate chemistry.
[216] Didier Boturyn,et al. A convenient access to α V β 3 /α V β 5 integrin ligand conjugates: regioselective solid-phase functionalisation of an RGD based peptide , 2001 .
[217] P. Black,et al. αvβ3 and αvβ5 Integrin Expression in Glioma Periphery , 2001 .
[218] Sibylle Ziegler,et al. Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .
[219] C. Yoon,et al. alpha(6) Integrin is the main receptor of human papillomavirus type 16 VLP. , 2001, Biochemical and biophysical research communications.
[220] J. Witztum,et al. Circulating Autoantibodies to Oxidized LDL Correlate With Arterial Accumulation and Depletion of Oxidized LDL in LDL Receptor–Deficient Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[221] D. Taverna,et al. Reduced blood vessel formation and tumor growth in alpha5-integrin-negative teratocarcinomas and embryoid bodies. , 2001, Cancer research.
[222] A. Annila,et al. Inhibition of β2Integrin–Mediated Leukocyte Cell Adhesion by Leucine–Leucine–Glycine Motif–Containing Peptides , 2001, The Journal of cell biology.
[223] W. Diluzio,et al. Towards developing a non-SnCl2 formulation for RP444, a new radiopharmaceutical for thrombus imaging. , 2001, Journal of pharmaceutical sciences.
[224] S. Batra,et al. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[225] M. Béhé,et al. Imaging tumors with peptide-based radioligands. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[226] M. Welch,et al. Evaluation of radiolabeled type IV collagen fragments as potential tumor imaging agents. , 2001, Bioconjugate chemistry.
[227] Pojen P. Chen,et al. Human-Derived Anti-Oxidized LDL Autoantibody Blocks Uptake of Oxidized LDL by Macrophages and Localizes to Atherosclerotic Lesions In Vivo , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[228] T. Carmody,et al. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[229] K. O'Byrne,et al. Angiogenesis as a biomarker and target in cancer chemoprevention. , 2001, The Lancet. Oncology.
[230] D. Scheinberg,et al. Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.
[231] J. M. Harris,et al. Pegylation: a novel process for modifying pharmacokinetics. , 2001, Clinical pharmacokinetics.
[232] T. Quinn,et al. Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells. , 2001, Nuclear medicine and biology.
[233] Arnoud Sonnenberg,et al. Function and interactions of integrins , 2001, Cell and Tissue Research.
[234] E. Sage,et al. Regulation of interactions between cells and extracellular matrix: a command performance on several stages. , 2001, The Journal of clinical investigation.
[235] C. Van de Wiele,et al. Peptide radiopharmaceuticals for diagnosis and therapy , 2001, European Journal of Nuclear Medicine.
[236] F. Giancotti,et al. EGF-R signaling through Fyn kinase disrupts the function of integrin α6β4 at hemidesmosomes , 2001, The Journal of Cell Biology.
[237] A. Beck‐Sickinger,et al. Peptides as carrier for tumor diagnosis and treatment. , 2001, Current medicinal chemistry. Anti-cancer agents.
[238] Thilo Stehle,et al. Crystal Structure of the Extracellular Segment of Integrin αVβ3 , 2001, Science.
[239] Deepak L. Bhatt,et al. Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists: A Meta-Analysis of Phase III Multicenter Randomized Trials , 2001, Circulation.
[240] B. Neustadt,et al. Inhibition of Angiogenesis and Tumor Growth by SCH221153, a Dual αvβ3 and αvβ5 Integrin Receptor Antagonist , 2001 .
[241] R. Taillefer,et al. Radiolabeled peptides in the detection of deep venous thrombosis. , 2001, Seminars in nuclear medicine.
[242] R. Califf,et al. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). , 2001, The American journal of cardiology.
[243] S. Denardo,et al. Antiangiogenic agents and their promising potential in combined therapy. , 2001, Critical reviews in oncology/hematology.
[244] M Schwaiger,et al. Tumor angiogenesis targeting using imaging agents. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[245] P. Low,et al. Folate-mediated targeting: from diagnostics to drug and gene delivery. , 2001, Drug discovery today.
[246] Hiroyuki Shimada,et al. Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an &agr;v Integrin Antagonist , 2001, Neurosurgery.
[247] R Weissleder,et al. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. , 2001, Radiology.
[248] M Schwaiger,et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[249] P. Speight,et al. αvβ6 Integrin Upregulates Matrix Metalloproteinase 9 and Promotes Migration of Normal Oral Keratinocytes , 2001 .
[250] K. Ward,et al. Antagonism of the Osteoclast Vitronectin Receptor with an Orally Active Nonpeptide Inhibitor Prevents Cancellous Bone Loss in the Ovariectomized Rat , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[251] Ralph Weissleder,et al. In vivo molecular target assessment of matrix metalloproteinase inhibition , 2001, Nature Medicine.
[252] P. Yock,et al. Intravascular ultrasound: novel pathophysiological insights and current clinical applications. , 2001, Circulation.
[253] David A. Cheresh,et al. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins , 2001, The Journal of cell biology.
[254] C Georg,et al. Noninvasive detection and evaluation of atherosclerotic coronary plaques with multislice computed tomography. , 2001, Journal of the American College of Cardiology.
[255] A. Schmermund,et al. Unstable coronary plaque and its relation to coronary calcium. , 2001, Circulation.
[256] M. Schwaiger,et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[257] L. Parise,et al. Activation of sickle red blood cell adhesion via integrin-associated protein/CD47-induced signal transduction. , 2001, The Journal of clinical investigation.
[258] M. Welch,et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[259] V. Fuster,et al. Clinical Imaging of the High-Risk or Vulnerable Atherosclerotic Plaque , 2001, Circulation research.
[260] C. Damsky,et al. β1-Class Integrins Regulate the Development of Laminae and Folia in the Cerebral and Cerebellar Cortex , 2001, Neuron.
[261] R. Benjamin,et al. Pilot study of vitaxin—an angiogenesis inhibitor—in patients with advanced leiomyosarcomas , 2001, Cancer.
[262] Deepak L. Bhatt,et al. Oral glycoprotein IIb/IIIa inhibitors: why don't they work? , 2001, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[263] David A. Calderwood,et al. The Phosphotyrosine Binding-like Domain of Talin Activates Integrins* , 2002, The Journal of Biological Chemistry.
[264] Takao Sakai,et al. Integrins in invasive growth. , 2002, The Journal of clinical investigation.
[265] M. Spieth,et al. A tabulated summary of the FDG PET literature. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[266] R. Aster,et al. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. , 2002, Blood.
[267] Napoleone Ferrara,et al. VEGF and the quest for tumour angiogenesis factors , 2002, Nature Reviews Cancer.
[268] S. Gambhir. Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.
[269] G. Rice,et al. αvβ6 Integrin-A Marker for the Malignant Potential of Epithelial Ovarian Cancer , 2002 .
[270] Zaverio M. Ruggeri,et al. Platelets in atherothrombosis , 2002, Nature Medicine.
[271] M. Yeager,et al. Three-dimensional model of the human platelet integrin αIIbβ3 based on electron cryomicroscopy and x-ray crystallography , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[272] Divalent cations and the relationship between αA and βA domains in integrins , 2002 .
[273] W. Chan,et al. Diagnosis of deep vein thrombosis and pulmonary embolism in pregnancy. , 2002, Thrombosis research.
[274] R. Fässler,et al. Matrix assembly, regulation, and survival functions of laminin and its receptors in embryonic stem cell differentiation , 2002, The Journal of cell biology.
[275] P J de Feyter,et al. New coronary imaging techniques: what to expect? , 2002, Heart.
[276] Thilo Stehle,et al. Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand , 2002, Science.
[277] W. Oyen,et al. Tumor Targeting with Radiolabeled v 3 Integrin Binding Peptides in a Nude Mouse Model , 2002 .
[278] K. Pienta,et al. The Role of αvβ3 in Prostate Cancer Progression , 2002 .
[279] K. Preissner,et al. Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes , 2002, Nature Medicine.
[280] W. Hagmann,et al. Effects of VLA-4 antagonists in rat whole embryo culture. , 2002, Teratology.
[281] W. Oyen,et al. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. , 2002, Cancer biotherapy & radiopharmaceuticals.
[282] N. Ahmed,et al. Integrin expression in colon cancer cells is regulated by the cytoplasmic domain of the β6 integrin subunit , 2002, International journal of cancer.
[283] G. Rice,et al. Overexpression of αvβ6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade , 2002 .
[284] D. Edwards,et al. Fundamentals of Receptor-Based Diagnostic Metalloradiopharmaceuticals , 2002 .
[285] David A. Cheresh,et al. Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.
[286] S. Murphy,et al. Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. , 2002, American heart journal.
[287] Thomas Beyer,et al. A combined PET/CT scanner: the path to true image fusion. , 2002, The British journal of radiology.
[288] D. Taverna,et al. Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins , 2002, Nature Medicine.
[289] R. Weissleder,et al. Optical-based molecular imaging: contrast agents and potential medical applications , 2003, European Radiology.
[290] D. Goldenberg. Targeted therapy of cancer with radiolabeled antibodies. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[291] J. Folkman. Role of angiogenesis in tumor growth and metastasis. , 2002, Seminars in oncology.
[292] J. Blum,et al. Small peptide radiopharmaceuticals in the imaging of acute thrombus. , 2002, Current pharmaceutical design.
[293] Manfred Schwab,et al. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. , 2002, Cancer research.
[294] P. Speight,et al. Binding of TGF-β1 latency-associated peptide (LAP) to αvβ6 integrin modulates behaviour of squamous carcinoma cells , 2002, British Journal of Cancer.
[295] W. Oyen,et al. Assessment of Prosthetic Vascular Graft Thrombogenicity Using the Technetium-99m Labeled Glycoprotein IIb/IIIa Receptor Antagonist DMP444 in a Dog Model , 2002, Cardiovascular surgery.
[296] D. Sheppard,et al. The EIIIA Segment of Fibronectin Is a Ligand for Integrins α9β1 and α4β1Providing a Novel Mechanism for Regulating Cell Adhesion by Alternative Splicing* , 2002, The Journal of Biological Chemistry.
[297] M. Thakur,et al. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. , 2002, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[298] Richard O Hynes,et al. Integrins Bidirectional, Allosteric Signaling Machines , 2002, Cell.
[299] Horst Kessler,et al. The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction. , 2002, Angewandte Chemie.
[300] K. Weinberg,et al. αv‐Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin , 2002, International journal of cancer.
[301] Shaker A Mousa,et al. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. , 2002, Current opinion in chemical biology.
[302] Kathleen R. Lamborn,et al. Cilengitide Targeting of αvβ3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts , 2002 .
[303] R. Aster,et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. , 2002, Blood.
[304] C. Contag,et al. It's not just about anatomy: In vivo bioluminescence imaging as an eyepiece into biology , 2002, Journal of magnetic resonance imaging : JMRI.
[305] I. Lamster,et al. The diagnostic applications of saliva--a review. , 2002, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[306] A. Giannetti,et al. Transforming Growth Factor-/ l Modulates # 1 and / 5 Integrin Receptors and Induces the de novo Expression of the ctv / 36 Heterodimer in Normal Human Keratinocytes : Implications for Wound Healing , 2002 .
[307] Zhihong Zhu,et al. In Vitro and in Vivo Evaluation of a Technetium-99m-Labeled Cyclic RGD Peptide as a Specific Marker of αVβ3 Integrin for Tumor Imaging , 2002 .
[308] L. Alberio,et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface , 2002, Nature.
[309] P. Hahnfeldt,et al. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.
[310] R. Alon,et al. From rolling to arrest on blood vessels: leukocyte tap dancing on endothelial integrin ligands and chemokines at sub-second contacts. , 2002, Seminars in immunology.
[311] Junichi Takagi,et al. Global Conformational Rearrangements in Integrin Extracellular Domains in Outside-In and Inside-Out Signaling , 2002, Cell.
[312] Jun Qin,et al. A Structural Mechanism of Integrin αIIbβ3 “Inside-Out” Activation as Regulated by Its Cytoplasmic Face , 2002, Cell.
[313] Antonio Colombo,et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. , 2003, Circulation.
[314] Horst Kessler,et al. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. , 2003, Biomaterials.
[315] L. Lau,et al. Identification of a Novel Integrin α6β1 Binding Site in the Angiogenic Inducer CCN1 (CYR61)* , 2003, Journal of Biological Chemistry.
[316] Junichi Takagi,et al. Structures of the αL I Domain and Its Complex with ICAM-1 Reveal a Shape-Shifting Pathway for Integrin Regulation , 2003, Cell.
[317] J. Frangioni. In vivo near-infrared fluorescence imaging. , 2003, Current opinion in chemical biology.
[318] Yunpeng Ye,et al. Synthesis and characterization of a macrocyclic near-infrared optical scaffold. , 2003, Journal of the American Chemical Society.
[319] S. Walsh,et al. Improved Pharmacokinetics and Reduced Antibody Reactivity of Lysostaphin Conjugated to Polyethylene Glycol , 2003, Antimicrobial Agents and Chemotherapy.
[320] K. Dixon. The radiation biology of radioimmunotherapy. , 2003, Nuclear medicine communications.
[321] T. Mikkelsen,et al. Angiogenesis in glioma: molecular mechanisms and roadblocks to translation. , 2003, Cancer journal.
[322] Thilo Stehle,et al. New insights into the structural basis of integrin activation. , 2003, Blood.
[323] S. Gambhir,et al. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.
[324] Jacques J. Peschon,et al. Semaphorin 7A promotes axon outgrowth through integrins and MAPKs , 2003, Nature.
[325] D. Mager,et al. Simultaneous Modeling of Abciximab Plasma Concentrations and ex Vivo Pharmacodynamics in Patients Undergoing Coronary Angioplasty , 2003, Journal of Pharmacology and Experimental Therapeutics.
[326] S. Robinson,et al. Design, synthesis, and evaluation of radiolabeled integrin αvβ3 receptor antagonists for tumor imaging and radiotherapy , 2003 .
[327] J. Fichna,et al. Synthesis of target-specific radiolabeled peptides for diagnostic imaging. , 2003, Bioconjugate chemistry.
[328] S. Watson,et al. Platelet-collagen interaction: is GPVI the central receptor? , 2003, Blood.
[329] F. Watt,et al. Suprabasal α6β4 integrin expression in epidermis results in enhanced tumourigenesis and disruption of TGFβ signalling , 2003, Journal of Cell Science.
[330] A. Sonnenberg,et al. Analysis of the interactions between BP180, BP230, plectin and the integrin α6β4 important for hemidesmosome assembly , 2003, Journal of Cell Science.
[331] P. D. de Feyter,et al. Noninvasive visualization of atherosclerotic plaque with electron beam and multislice spiral computed tomography. , 2003, Journal of interventional cardiology.
[332] Eric R. Prossnitz,et al. FRET Detection of Cellular α4-Integrin Conformational Activation , 2003 .
[333] W. Oyen,et al. Evaluation of Tc-99m-labeled glycoprotein IIb/IIIa receptor antagonist DMP444 SPECT in patients with infective endocarditis. , 2003, Clinical nuclear medicine.
[334] Jeffrey W. Smith. Cilengitide Merck. , 2003, Current opinion in investigational drugs.
[335] G. Renda,et al. Effect of fibrinogen concentration and platelet count on the inhibitory effect of abciximab and tirofiban , 2003, Thrombosis and Haemostasis.
[336] Minsoo Kim,et al. Bidirectional Transmembrane Signaling by Cytoplasmic Domain Separation in Integrins , 2003, Science.
[337] D Bentley,et al. Highly parallel SNP genotyping. , 2003, Cold Spring Harbor symposia on quantitative biology.
[338] Samuel A. Wickline,et al. Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With &agr;v&bgr;3-Integrin–Targeted Nanoparticles , 2003 .
[339] C. Carman,et al. Integrin avidity regulation: are changes in affinity and conformation underemphasized? , 2003, Current opinion in cell biology.
[340] Timothy A. Springer,et al. Therapeutic antagonists and conformational regulation of integrin function , 2003, Nature Reviews Drug Discovery.
[341] M. E. Kooi,et al. Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by In Vivo Magnetic Resonance Imaging , 2003, Circulation.
[342] R. Taillefer,et al. Imaging characteristics of a novel technetium Tc 99m-labeled platelet glycoprotein IIb/IIIa receptor antagonist in patients With acute deep vein thrombosis or a history of deep vein thrombosis. , 2003, Archives of internal medicine.
[343] M. Lebwohl,et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. , 2003, The New England journal of medicine.
[344] P. Choyke,et al. Imaging of angiogenesis: from microscope to clinic , 2003, Nature Medicine.
[345] R. Wahl,et al. PET-CT detection of abdominal recurrence of ovarian cancer: radiologic–surgical correlation , 2004, Abdominal Imaging.
[346] David H. Miller,et al. A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.
[347] A. Reynolds,et al. Integrins in angiogenesis: multitalented molecules in a balancing act , 2003, Cell and Tissue Research.
[348] R. Valkema,et al. Radiolabelled peptides for tumour therapy: current status and future directions , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[349] S. Galbraith,et al. Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development. , 2003, The British journal of radiology.
[350] R. Liddington,et al. Talin Binding to Integrin ß Tails: A Final Common Step in Integrin Activation , 2003, Science.
[351] M. Schwaiger,et al. Radiotracer-based strategies to image angiogenesis. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[352] David A Calderwood,et al. Integrin β cytoplasmic domain interactions with phosphotyrosine-binding domains: A structural prototype for diversity in integrin signaling , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[353] M. Tomasson,et al. Platelet and osteoclast β3 integrins are critical for bone metastasis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[354] A. Kassner,et al. Molecular Imaging of Angiogenesis in Nascent Vx-2 Rabbit Tumors Using a Novel ανβ3-targeted Nanoparticle and 1.5 Tesla Magnetic Resonance Imaging , 2003 .
[355] T. Minamoto,et al. Expression of αv Integrin Family in Gastric Carcinomas: Increased αvβ6 is Associated with Lymph Node Metastasis , 2003 .
[356] R. Liddington,et al. Structural determinants of integrin recognition by talin. , 2003, Molecular cell.
[357] Jonathan R. Lindner,et al. Noninvasive Assessment of Angiogenesis by Ultrasound and Microbubbles Targeted to &agr;v-Integrins , 2003, Circulation.
[358] E. Even-Sapir,et al. Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[359] J. Brugge,et al. Src kinase activation by direct interaction with the integrin β cytoplasmic domain , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[360] R. Weissleder,et al. Synthesis and Properties of Sulfhydryl-Reactive Near-Infrared Cyanine Fluorochromes for Fluorescence Imaging , 2003, Molecular imaging.
[361] Horst Kessler,et al. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. , 2003, Chemistry.
[362] Junichi Takagi,et al. Structure of integrin α5β1 in complex with fibronectin , 2003, The EMBO journal.
[363] Shuang Liu,et al. Anaerobic 90Y- and 177Lu-labeling of a DOTA-conjugated nonpeptide vitronectin receptor antagonist. , 2003, Bioconjugate chemistry.
[364] W. Oyen,et al. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. , 2004, Cancer biotherapy & radiopharmaceuticals.
[365] C. Caussin,et al. Characterization of vulnerable nonstenotic plaque with 16-slice computed tomography compared with intravascular ultrasound. , 2004, The American journal of cardiology.
[366] H. Oettle,et al. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. , 2004, Oral oncology.
[367] M. P. Bernarducci. Radiolabeled peptides: overcoming the challenges of post-surgical patient management of venous thromboembolism. , 2004, Surgical technology international.
[368] A. Mercurio,et al. The Met Receptor and α6β4 Integrin Can Function Independently to Promote Carcinoma Invasion* , 2004, Journal of Biological Chemistry.
[369] R. Hebbel,et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. , 2004, Blood.
[370] H. Jin,et al. Integrins: roles in cancer development and as treatment targets , 2004, British Journal of Cancer.
[371] T. Sakuma,et al. Molecular imaging identifies regions with microthromboemboli during primary angioplasty in acute coronary thrombosis. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[372] W. Chuang,et al. Solution structure of γ‐bungarotoxin: The functional significance of amino acid residues flanking the RGD motif in integrin binding , 2004, Proteins.
[373] P. Angelberger,et al. Low density lipoprotein labelling characterizes experimentally induced atherosclerotic lesions in rabbits in vivo as to presence of foam cells and endothelial coverage , 2004, European Journal of Nuclear Medicine.
[374] K. Ramos,et al. Regulation of alpha7-integrin expression in vascular smooth muscle by injury-induced atherosclerosis. , 2004, American journal of physiology. Heart and circulatory physiology.
[375] J. Takagi,et al. A Specific Interface between Integrin Transmembrane Helices and Affinity for Ligand , 2004, PLoS biology.
[376] C. Tung,et al. Fluorescent peptide probes for in vivo diagnostic imaging , 2004, Biopolymers.
[377] R. Jordan,et al. Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibodyof c7E3 Fab (abciximab; ReoProTM) , 2004, Angiogenesis.
[378] R. Hynes,et al. The spatial and temporal expression patterns of integrin α9β1 and one of its ligands, the EIIIA segment of fibronectin, in cutaneous wound healing , 2004 .
[379] Ernst J. Rummeny,et al. Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[380] W. Muller,et al. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. , 2004, Cancer cell.
[381] M. Brechbiel,et al. Antibody-targeted radiation cancer therapy , 2004, Nature Reviews Drug Discovery.
[382] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[383] Integrin activation , 2004, Journal of Cell Science.
[384] J. Iredale,et al. Engagement of αvβ3 Integrin Regulates Proliferation and Apoptosis of Hepatic Stellate Cells* , 2004, Journal of Biological Chemistry.
[385] D. Hanahan,et al. Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring. , 2004, Journal of immunotherapy.
[386] R. Hwang,et al. The role of integrins in tumor angiogenesis. , 2004, Hematology/oncology clinics of North America.
[387] Ryan Park,et al. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[388] Y. Wada,et al. Molecular Dissection of the α-Dystroglycan- and Integrin-binding Sites within the Globular Domain of Human Laminin-10* , 2004, Journal of Biological Chemistry.
[389] J. Peter-Katalinic,et al. Recombinant human laminin-5 domains. Effects of heterotrimerization, proteolytic processing, and N-glycosylation on alpha3beta1 integrin binding. , 2004, The Journal of biological chemistry.
[390] K. Camphausen,et al. Optical imaging of mice in oncologic research , 2004, Expert review of anticancer therapy.
[391] J. Bading,et al. Micro-PET Imaging of αvβ3-Integrin Expression with 18F-Labeled Dimeric RGD Peptide , 2004 .
[392] M. Trikha,et al. CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo , 2004, International journal of cancer.
[393] Ryan Park,et al. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. , 2004, Bioconjugate chemistry.
[394] Wenjun Guo,et al. Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.
[395] Eva M. Sevick-Muraca,et al. Near-Infrared Optical Imaging of Integrin αvβ3 in Human Tumor Xenografts , 2004 .
[396] K. Ley,et al. Trafficking of natural killer cells. , 2004, Current molecular medicine.
[397] E. Ohman,et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[398] J. Bading,et al. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. , 2004, Nuclear medicine and biology.
[399] R. Moats,et al. In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts , 2004, Cancer Research.
[400] T. Tsuji. Physiological and Pathological Roles of α3β1 Integrin , 2004, The Journal of Membrane Biology.
[401] P. Bohlen,et al. VEGF‐A promotes tissue repair‐associated lymphatic vessel formation via VEGFR‐2 and the α1β1 and α2β1 integrins , 2004 .
[402] Michael S. Pepper,et al. αvβ3 and αvβ5 integrin antagonists inhibit angiogenesis in vitro , 2004, Angiogenesis.
[403] T. Lüscher,et al. Molecular Imaging of Atherosclerotic Plaques Using a Human Antibody Against the Extra-Domain B of Fibronectin , 2004, Circulation research.
[404] M. Schwaiger,et al. Synthesis and biological evaluation of a 99mTc-labelled cyclic RGD peptide for imaging the αvβ3 expression , 2004, Nuklearmedizin.
[405] C. Gahmberg,et al. Intracellular and Cell Surface Localization of a Complex between αMβ2 Integrin and Promatrix Metalloproteinase-9 Progelatinase in Neutrophils1 , 2004, The Journal of Immunology.
[406] D. Dione,et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. , 2004, The Journal of clinical investigation.
[407] Horst Kessler,et al. Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[408] M. Schwaiger,et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. , 2004, Bioconjugate chemistry.
[409] B. Jensen,et al. Estimating Mass Balance for Inhaled Drugs in Humans: An Example with a VLA‐4 Antagonist, IVL745 , 2004, Journal of clinical pharmacology.
[410] Michael D Schaller,et al. The interplay between Src and integrins in normal and tumor biology , 2004, Oncogene.
[411] P. Weissberg,et al. Molecular and metabolic imaging of atherosclerosis. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[412] G. Thomas,et al. The Integrin Cytoplasmic-tail Motif EKQKVDLSTDC Is Sufficient to Promote Tumor Cell Invasion Mediated by Matrix Metalloproteinase (MMP)-2 or MMP-9* , 2004, Journal of Biological Chemistry.
[413] B. Bergmann,et al. Different embryo-fetal toxicity effects for three VLA-4 antagonists. , 2004, Birth defects research. Part B, Developmental and reproductive toxicology.
[414] N. Boudreau,et al. The Homeobox Transcription Factor Hox D3 Promotes Integrin α5β1 Expression and Function during Angiogenesis* , 2004, Journal of Biological Chemistry.
[415] K. Nicolay,et al. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. , 2004, Bioconjugate chemistry.
[416] Ultrasonic analysis of peptide- And antibody-targeted microbubble contrast agents for molecular imaging of α vβ 3-expressing cells , 2004 .
[417] G. von Heijne,et al. Determination of N- and C-terminal Borders of the Transmembrane Domain of Integrin Subunits* , 2004, Journal of Biological Chemistry.
[418] S. Bhatia,et al. Probing the Cytotoxicity Of Semiconductor Quantum Dots. , 2004, Nano letters.
[419] Peter S. Conti,et al. Pegylated Arg-Gly-Asp Peptide: 64Cu Labeling and PET Imaging of Brain Tumor αvβ3-Integrin Expression , 2004 .
[420] Sharon-Lise T. Normand,et al. Coronary Artery Spatial Distribution of Acute Myocardial Infarction Occlusions , 2004, Circulation.
[421] Jean-Luc Coll,et al. Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis. , 2004, Journal of the American Chemical Society.
[422] David H. Miller,et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis , 2004, Journal of Neurology.
[423] Zahi A. Fayad,et al. Molecular, cellular and functional imaging of atherothrombosis , 2004, Nature Reviews Drug Discovery.
[424] Bing Xu,et al. Facile one-pot synthesis of bifunctional heterodimers of nanoparticles: a conjugate of quantum dot and magnetic nanoparticles. , 2004, Journal of the American Chemical Society.
[425] H. Saitoh,et al. Prodrug and Analog Approaches to Improving the Intestinal Absorption of a Cyclic Peptide, GPIIb/IIIa Receptor Antagonist , 1997, Pharmaceutical Research.
[426] Rex Moats,et al. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. , 2004, Nuclear medicine and biology.
[427] René M. Botnar,et al. In Vivo Molecular Imaging of Acute and Subacute Thrombosis Using a Fibrin-Binding Magnetic Resonance Imaging Contrast Agent , 2004, Circulation.
[428] S. Nie,et al. In vivo cancer targeting and imaging with semiconductor quantum dots , 2004, Nature Biotechnology.
[429] F. Kolodgie,et al. Regulation of Macrophage Foam Cell Formation by αVβ3 Integrin : Potential Role in Human Atherosclerosis , 2004 .
[430] Juan J. Badimon,et al. Plaque Neovascularization Is Increased in Ruptured Atherosclerotic Lesions of Human Aorta: Implications for Plaque Vulnerability , 2004, Circulation.
[431] K. Schrör,et al. Comparative Pharmacology of GP IIb/IIIa Antagonists , 2003, Journal of Thrombosis and Thrombolysis.
[432] M. Schwaiger,et al. Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation , 2004 .
[433] Shuang Liu,et al. The role of coordination chemistry in the development of target-specific radiopharmaceuticals. , 2004, Chemical Society reviews.
[434] R. Osarogiagbon,et al. The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic Vasculopathy , 2004, Microcirculation.
[435] Subhani M Okarvi,et al. Peptide‐based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseases , 2004, Medicinal research reviews.
[436] Barry S. Coller,et al. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics , 2004, Nature.
[437] R. Haubner,et al. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. , 2004, Current pharmaceutical design.
[438] D. Desmecht,et al. Characterization of the caprine (Capra hircus) beta-2 integrin CD18-encoding cDNA and identification of mutations potentially responsible for the ruminant-specific virulence of Mannheimia haemolytica , 2004, Molecular membrane biology.
[439] P. Faries,et al. Type I collagen synergistically enhances PDGF-induced smooth muscle cell proliferation through pp60src-dependent crosstalk between the α2β1 integrin and PDGFβ receptor , 2004 .
[440] S. Goodman,et al. Immunohistochemical screening for β6‐integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up‐regulation in pancreatic ductal adenocarcinomas in vivo and in vitro , 2004 .
[441] P. Angelberger,et al. Autologous low-density lipoprotein labelling allows characterization of human atherosclerotic lesions in vivo as to presence of foam cells and endothelial coverage , 2004, European Journal of Nuclear Medicine.
[442] E. W. Meijer,et al. Design and synthesis of a bimodal target-specific contrast agent for angiogenesis. , 2004, Organic letters.
[443] Ralph Weissleder,et al. Detection of Vascular Adhesion Molecule-1 Expression Using a Novel Multimodal Nanoparticle , 2005, Circulation research.
[444] H. Amthauer,et al. Detection of Recurrent Pancreatic Cancer: Comparison of FDG-PET with CT/MRI , 2005, Pancreatology.
[445] B. Saville,et al. Absence of Adverse Effects in Cynomolgus Macaques Treated with CNTO 95, a Fully Human Anti-αv Integrin Monoclonal Antibody, Despite Widespread Tissue Binding , 2005, Clinical Cancer Research.
[446] M. Ginsberg,et al. Integrin regulation. , 2005, Current opinion in cell biology.
[447] S. Colucci,et al. Binding of osteopontin to the osteoclast integrin αvβ3 , 2005, Osteoporosis International.
[448] Shi Ke,et al. Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe. , 2005, Journal of biomedical optics.
[449] Ralph Weissleder,et al. Molecular imaging in the clinical arena. , 2005, JAMA.
[450] S. Mohammed,et al. Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. , 2005, Bioconjugate chemistry.
[451] R. Weissleder,et al. Tomographic fluorescence mapping of tumor targets. , 2005, Cancer research.
[452] R. Bates. The αvβ6 integrin as a novel molecular target for colorectal cancer , 2005 .
[453] D. Sheppard,et al. The Lymphangiogenic Vascular Endothelial Growth Factors VEGF-C and -D Are Ligands for the Integrin α9β1* , 2005, Journal of Biological Chemistry.
[454] F. Saltel,et al. The mechanisms and dynamics of αvβ3 integrin clustering in living cells , 2005, The Journal of cell biology.
[455] Kit S Lam,et al. Near-Infrared Optical Imaging of Ovarian Cancer Xenografts with Novel α3-Integrin Binding Peptide “OA02” , 2005, Molecular imaging.
[456] C. Olbrich,et al. Optical imaging in drug discovery and diagnostic applications. , 2005, Advanced drug delivery reviews.
[457] R. Alon,et al. Immune cell migration in inflammation: present and future therapeutic targets , 2005, Nature Immunology.
[458] M. Nguyen,et al. Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. , 2005, Blood.
[459] King C.P. Li,et al. A review: Integrin αvβ3-targeted molecular imaging and therapy in angiogenesis , 2005 .
[460] M. Shimaoka,et al. An atomic resolution view of ICAM recognition in a complex between the binding domains of ICAM-3 and integrin αLβ2 , 2005 .
[461] I. Ojima,et al. Recent advances in tumor-targeting anticancer drug conjugates. , 2005, Bioorganic & medicinal chemistry.
[462] M. Schwaiger,et al. Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[463] K. Tyler,et al. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. , 2005, The New England journal of medicine.
[464] J. Sanes,et al. A simplified laminin nomenclature. , 2005, Matrix biology : journal of the International Society for Matrix Biology.
[465] Sanjiv S. Gambhir,et al. Near-Infrared Fluorescent RGD Peptides for Optical Imaging of Integrin αvβ3 Expression in Living Mice , 2005 .
[466] M. Schwaiger,et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[467] Michael E. Phelps,et al. Usefulness of 3′-[F-18]Fluoro-3′-deoxythymidine with Positron Emission Tomography in Predicting Breast Cancer Response to Therapy , 2005, Molecular Imaging and Biology.
[468] M. Arnaout,et al. Integrin structure, allostery, and bidirectional signaling. , 2005, Annual review of cell and developmental biology.
[469] P. Rutgeerts,et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. , 2005, The New England journal of medicine.
[470] Tim Liedl,et al. Cytotoxicity of colloidal CdSe and CdSe/ZnS nanoparticles. , 2005, Nano letters.
[471] Weibo Cai,et al. Multimodality tumor imaging targeting integrin α v β 3 , 2005 .
[472] M. Ferrari. Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.
[473] Hans-Jü Rgen Wester. Molecular Targeting with Peptides or Peptide-Polymer Conjugates: Just a Question of Size? , 2005 .
[474] A. Górski,et al. The Biological Functions of β 3 Integrins ( β 3 integrins / α IIb β 3 integrin / α v β 3 integrin / biological functions ) , 2005 .
[475] Grace Hu,et al. Molecular MR imaging of melanoma angiogenesis with ανβ3‐targeted paramagnetic nanoparticles , 2005, Magnetic resonance in medicine.
[476] A. Padhani,et al. Imaging tumour angiogenesis , 2005, Cancer imaging : the official publication of the International Cancer Imaging Society.
[477] Antony K. Chen,et al. Superparamagnetic Iron Oxide Nanoparticle Probes for Molecular Imaging , 2006, Annals of Biomedical Engineering.
[478] R. Kerbel,et al. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. , 2005, Breast.
[479] M. Schirner,et al. Sensitive Particle Acoustic Quantification (SPAQ): A New Ultrasound-Based Approach for the Quantification of Ultrasound Contrast Media in High Concentrations , 2005, Investigative Radiology.
[480] S. Gambhir,et al. microPET Imaging of Glioma Integrin αvβ3 Expression Using 64Cu-Labeled Tetrameric RGD Peptide , 2005 .
[481] T. Sakuma,et al. Simultaneous integrin alphavbeta3 and glycoprotein IIb/IIIa inhibition causes reduction in infarct size in a model of acute coronary thrombosis and primary angioplasty. , 2005, Cardiovascular research.
[482] R. Hwang,et al. Integrin α4β1–VCAM-1–mediated adhesion between endothelial and mural cells is required for blood vessel maturation , 2005 .
[483] J. Qin,et al. VEGF-integrin interplay controls tumor growth and vascularization. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[484] R. Jain. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.
[485] M. Krix. Quantification of enhancement in contrast ultrasound: a tool for monitoring of therapies in liver metastases , 2005, European radiology.
[486] Napoleone Ferrara,et al. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. , 2005, Cancer research.
[487] Horst Kessler,et al. Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD , 2005, PLoS medicine.
[488] R. Fässler,et al. β 1 integrin function in vivo: Adhesion, migration and more , 2005, Cancer and Metastasis Reviews.
[489] M. Brechbiel,et al. Auger electrons: lethal, low energy, and coming soon to a tumor cell nucleus near you. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[490] T. Kinashi,et al. Intracellular signalling controlling integrin activation in lymphocytes , 2005, Nature Reviews Immunology.
[491] S. Gambhir,et al. Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics , 2005, Science.
[492] H. Horvitz,et al. MicroRNA expression profiles classify human cancers , 2005, Nature.
[493] Arion F Chatziioannou,et al. Instrumentation for molecular imaging in preclinical research: Micro-PET and Micro-SPECT. , 2005, Proceedings of the American Thoracic Society.
[494] S. Robinson,et al. Radiolabeled Integrin αvβ3 Antagonists as Radiopharmaceuticals for Tumor Radiotherapy , 2005 .
[495] Byron Ballou,et al. Fluorescence imaging of tumors in vivo. , 2005, Current medicinal chemistry.
[496] P. Oettgen,et al. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. , 2005, The Journal of clinical investigation.
[497] R. Recker,et al. Effect of L-000845704, an αVβ3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women , 2005 .
[498] S. Holgate,et al. Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma. , 2005, The Journal of allergy and clinical immunology.
[499] M. Gulumian. An Update on the Detoxification Processes for Silica Particles and Asbestos Fibers: Successess and Limitations , 2005, Journal of toxicology and environmental health. Part B, Critical reviews.
[500] Donghoon Lee,et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. , 2005, Nano letters.
[501] Klaas Nicolay,et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[502] Kuan-Der Lee,et al. Plasma antigen levels of thrombin-activatable fibrinolysis inhibitor did not differ in patients with or without disseminated intravascular coagulation , 2005, Annals of Hematology.
[503] S. Kaul,et al. Assessment of Endogenous and Therapeutic Arteriogenesis by Contrast Ultrasound Molecular Imaging of Integrin Expression , 2005, Circulation.
[504] Eva M. Sevick-Muraca,et al. Quantifying molecular specificity of αvβ3 integrin-targeted optical contrast agents with dynamic optical imaging , 2005 .
[505] P. Sterk,et al. Effect of a very late antigen‐4 receptor antagonist on allergen‐induced airway responses and inflammation in asthma , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[506] K. Balasubramanian,et al. Chemically functionalized carbon nanotubes. , 2005, Small.
[507] Britton Chance,et al. Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[508] D. Boturyn,et al. Activatable Fluorescent Probes for Tumour‐Targeting Imaging in Live Mice , 2006, ChemMedChem.
[509] Jinwoo Cheon,et al. Dual-mode nanoparticle probes for high-performance magnetic resonance and fluorescence imaging of neuroblastoma. , 2006, Angewandte Chemie.
[510] M. Schwartz,et al. Matrix-specific suppression of integrin activation in shear stress signaling. , 2006, Molecular biology of the cell.
[511] Rinaldo Cubeddu,et al. Comparison of noncontact and fiber-based fluorescence-mediated tomography. , 2006, Optics letters.
[512] W. Heindel,et al. In vivo imaging of integrin ανβ3 expression using fluorescence-mediated tomography , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[513] Rebecca Richards-Kortum,et al. Oral premalignancy: New methods of detection and treatment , 2006, Current oncology reports.
[514] A. Fangberget,et al. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[515] S. Kennel,et al. Integrin Regulation by Vascular Endothelial Growth Factor in Human Brain Microvascular Endothelial Cells , 2006, Journal of Biological Chemistry.
[516] J. Haier,et al. Integrins in cancer treatment. , 2006, Current cancer drug targets.
[517] S. Fagerholm,et al. Interfering with leukocyte integrin activation—a novel concept in the development of anti‐inflammatory drugs , 2006, Annals of medicine.
[518] H. Shmeeda,et al. Pros and Cons of the Liposome Platform in Cancer Drug Targeting , 2006, Journal of liposome research.
[519] Ralph Weissleder,et al. Noninvasive Vascular Cell Adhesion Molecule-1 Imaging Identifies Inflammatory Activation of Cells in Atherosclerosis , 2006, Circulation.
[520] D J Collins,et al. Dynamic contrast‐enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis , 2006, The British journal of surgery.
[521] Adam Byron,et al. Integrin ligands at a glance , 2006, Journal of Cell Science.
[522] A. Bar-Or,et al. Altered CD 4 / CD 8 T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis , 2006 .
[523] M. Thakur,et al. Imaging thromboembolism with fibrin-avid 99mTc-peptide: evaluation in swine. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[524] Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[525] Ruiwu Liu,et al. Combinatorial chemistry identifies high-affinity peptidomimetics against α4β1 integrin for in vivo tumor imaging , 2006 .
[526] A. Cuthbertson,et al. NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. , 2006, Bioorganic & medicinal chemistry letters.
[527] C. Croce,et al. A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[528] T. Springer. Complement and the multifaceted functions of VWA and integrin I domains. , 2006, Structure.
[529] R. Longhi,et al. Spontaneous Formation of L-Isoaspartate and Gain of Function in Fibronectin* , 2006, Journal of Biological Chemistry.
[530] K. Rabe,et al. The effect of a single inhaled dose of a VLA‐4 antagonist on allergen‐induced airway responses and airway inflammation in patients with asthma , 2006, Allergy.
[531] J. Qin,et al. Regulation of integrin αIIbβ3 activation by distinct regions of its cytoplasmic tails , 2006 .
[532] Federico Bussolino,et al. Integrins and angiogenesis: a sticky business. , 2006, Experimental cell research.
[533] K. Katagiri,et al. Spatiotemporal regulation of the kinase Mst1 by binding protein RAPL is critical for lymphocyte polarity and adhesion , 2006, Nature Immunology.
[534] W. Oyen,et al. Improved targeting of the αvβ3 integrin by multimerisation of RGD peptides , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[535] D. Stupack,et al. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. , 2006, The Journal of clinical investigation.
[536] Robert C Brasch,et al. Imaging of tumor angiogenesis: current approaches and future prospects. , 2006, Current pharmaceutical design.
[537] A. Sonnenberg,et al. Multiple Functions of the Integrin α6β4 in Epidermal Homeostasis and Tumorigenesis , 2006, Molecular and Cellular Biology.
[538] S. Gambhir,et al. Quantitative PET Imaging of Tumor Integrin αvβ3 Expression with 18F-FRGD2 , 2006 .
[539] S. Acton,et al. Selectin ligands promote ultrasound contrast agent adhesion under shear flow. , 2006, Molecular pharmaceutics.
[540] G. Tucker. Integrins: Molecular targets in cancer therapy , 2006, Current oncology reports.
[541] Ralph Weissleder,et al. Molecular and cellular imaging of atherosclerosis: emerging applications. , 2006, Journal of the American College of Cardiology.
[542] Thomas Walz,et al. Activation of leukocyte beta2 integrins by conversion from bent to extended conformations. , 2006, Immunity.
[543] M. Sheetz,et al. Local force and geometry sensing regulate cell functions , 2006, Nature Reviews Molecular Cell Biology.
[544] B. Garmy-Susini,et al. Integrin α4β1 Promotes Monocyte Trafficking and Angiogenesis in Tumors , 2006 .
[545] M. Prato,et al. Carbon nanotubes as nanomedicines: from toxicology to pharmacology. , 2006, Advanced drug delivery reviews.
[546] Deepak L. Bhatt,et al. Antithrombotic therapy for percutaneous coronary intervention. , 2006, Cardiology clinics.
[547] Shuang Liu,et al. Impact of PKM linkers on biodistribution characteristics of the 99mTc-labeled cyclic RGDfK dimer. , 2006, Bioconjugate chemistry.
[548] Sanjiv S. Gambhir,et al. How molecular imaging is speeding up antiangiogenic drug development , 2006, Molecular Cancer Therapeutics.
[549] S. Cherry,et al. Simultaneous acquisition of multislice PET and MR images: initial results with a MR-compatible PET scanner. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[550] R. Haubner. Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis? , 2006, European journal of nuclear medicine and molecular imaging.
[551] P. Campochiaro,et al. Suppression and Regression of Choroidal Neovascularization by Systemic Administration of an α5β1 Integrin Antagonist , 2006, Molecular Pharmacology.
[552] Franz Buchegger,et al. Auger radiation targeted into DNA: a therapy perspective , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[553] Hyuing Zhang,et al. Characterization of digital waveforms using thermodynamic analogs: detection of contrast-targeted tissue in vivo , 2006, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.
[554] C. Pedone,et al. Peptide‐based Molecules in Angiogenesis , 2006, Chemical biology & drug design.
[555] D. Potenza,et al. Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids. , 2006, Bioorganic & medicinal chemistry.
[556] Sharon Bloch,et al. Targeting Beta-3 integrin using a linear hexapeptide labeled with a near-infrared fluorescent molecular probe. , 2006, Molecular pharmaceutics.
[557] Ralph Weissleder,et al. Nanoparticle imaging of integrins on tumor cells. , 2006, Neoplasia.
[558] John E. Johnson,et al. Fluorescent signal amplification of carbocyanine dyes using engineered viral nanoparticles. , 2006, Journal of the American Chemical Society.
[559] Weibo Cai,et al. A Thiol-Reactive 18F-Labeling Agent, N-[2-(4-18F-Fluorobenzamido)Ethyl]Maleimide, and Synthesis of RGD Peptide-Based Tracer for PET Imaging of αvβ3 Integrin Expression , 2006 .
[560] K. Sekiguchi,et al. Ligand-binding specificities of laminin-binding integrins: A comprehensive survey of laminin–integrin interactions using recombinant α3β1, α6β1, α7β1 and α6β4 integrins , 2006 .
[561] M. Schwaiger,et al. PET-Based Human Dosimetry of 18F-Galacto-RGD, a New Radiotracer for Imaging avb3 Expression , 2006 .
[562] C. Decristoforo,et al. [99mTc]HYNIC-RGD for imaging integrin αvβ3 expression , 2006 .
[563] Rebecca Richards-Kortum,et al. Optical molecular imaging agents for cancer diagnostics and therapeutics. , 2006, Nanomedicine.
[564] Bing Jia,et al. 99mTc-Labeled Cyclic RGDfK Dimer: Initial Evaluation for SPECT Imaging of Glioma Integrin αvβ3 Expression , 2006 .
[565] T. Byzova,et al. Integrin signaling is critical for pathological angiogenesis , 2006, The Journal of experimental medicine.
[566] Marcelino Bernardo,et al. Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging. , 2006, Nano letters.
[567] Nicholas A Peppas,et al. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.
[568] H. Friess,et al. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer , 2006, BMC Cancer.
[569] Horst Kessler,et al. Positron Emission Tomography Using [18F]Galacto-RGD Identifies the Level of Integrin αvβ3 Expression in Man , 2006, Clinical Cancer Research.
[570] Weibo Cai,et al. Near-Infrared Fluorescence Imaging of Tumor Integrin αvβ3 Expression with Cy7-Labeled RGD Multimers , 2006, Molecular Imaging and Biology.
[571] H. Kessler,et al. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. , 2006, Current pharmaceutical design.
[572] Chun Li,et al. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. , 2006, Nuclear medicine and biology.
[573] B. Turk. Targeting proteases: successes, failures and future prospects , 2006, Nature Reviews Drug Discovery.
[574] X. Bu,et al. EFFECT OF THE ANGIOGENESIS INHIBITOR CILENGITIDE (EMD 121974) ON GLIOBLASTOMA GROWTH IN NUDE MICE , 2006, Neurosurgery.
[575] D. Jonas,et al. CXCR4 Chemokine Receptor Mediates Prostate Tumor Cell Adhesion through α5 and β3 Integrins , 2006 .
[576] D. Hallahan,et al. Integrin αvβ3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non–small-cell lung cancer models , 2006 .
[577] R. Kerbel. Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer? , 2006, Science.
[578] Shuang Liu. Radiolabeled Multimeric Cyclic RGD Peptides as Integrin αvβ3 Targeted Radiotracers for Tumor Imaging , 2006 .
[579] Sanjiv S Gambhir,et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. , 2006, Nano letters.
[580] G. Loudos,et al. Comparative evaluation of linear and cyclic 99mTc-RGD peptides for targeting of integrins in tumor angiogenesis. , 2006, Anticancer research.
[581] Klaas Nicolay,et al. Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. , 2006, Nano letters.
[582] D. Boturyn,et al. Noninvasive Optical Imaging of Ovarian Metastases Using Cy5-labeled RAFT-c(-RGDfK-)4 , 2006, Molecular imaging.
[583] Sharon Bloch,et al. Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. , 2006, Journal of medicinal chemistry.
[584] Keishi Kitamura,et al. Performance characteristics of a new 3-dimensional continuous-emission and spiral-transmission high-sensitivity and high-resolution PET camera evaluated with the NEMA NU 2-2001 standard. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[585] Weibo Cai,et al. Anti-Angiogenic Cancer Therapy Based on Integrin αvβ3 Antagonism , 2006 .
[586] P. Campochiaro,et al. Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. , 2006, Molecular pharmacology.
[587] T. Livraghi,et al. Radiofrequency Ablation of Liver Tumors: The Role of Microbubble Ultrasound Contrast Agents , 2006, Ultrasound quarterly.
[588] Roland Haubner,et al. αvβ3-integrin imaging: a new approach to characterise angiogenesis? , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[589] M. Juweid. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. , 2006, Hematology. American Society of Hematology. Education Program.
[590] K. Miyazono,et al. Prox1 induces lymphatic endothelial differentiation via integrin alpha9 and other signaling cascades. , 2007, Molecular biology of the cell.
[591] R. M. Owen,et al. Selective tumor cell targeting using low-affinity, multivalent interactions. , 2007, ACS chemical biology.
[592] Vasilis Ntziachristos,et al. Fluorescence Tomography and Magnetic Resonance Imaging of Myocardial Macrophage Infiltration in Infarcted Myocardium In Vivo , 2007, Circulation.
[593] D. Sheppard,et al. Integrin α9β1 Directly Binds to Vascular Endothelial Growth Factor (VEGF)-A and Contributes to VEGF-A-induced Angiogenesis* , 2007, Journal of Biological Chemistry.
[594] Junichi Takagi,et al. Structural basis for ligand recognition by integrins. , 2007, Current opinion in cell biology.
[595] R. Sachleben,et al. Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agents. , 2007, Bioconjugate chemistry.
[596] Mark R Gilbert,et al. Chemoradiotherapy in malignant glioma: standard of care and future directions. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[597] T. Mikkelsen,et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[598] J. Roes,et al. Ulcerative colitis and autoimmunity induced by loss of myeloid αv integrins , 2007, Proceedings of the National Academy of Sciences.
[599] Weibo Cai,et al. Are quantum dots ready for in vivo imaging in human subjects? , 2007, Nanoscale research letters.
[600] S. Jurisson,et al. Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3. , 2007, Nuclear medicine and biology.
[601] K. Nicolay,et al. Anginex-conjugated liposomes for targeting of angiogenic endothelial cells. , 2007, Bioconjugate chemistry.
[602] Michael Loran Dustin,et al. Force as a facilitator of integrin conformational changes during leukocyte arrest on blood vessels and antigen-presenting cells. , 2007, Immunity.
[603] W. Oyen,et al. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. , 2007, Nuclear medicine and biology.
[604] J. Correia,et al. In vitro and in vivo evaluation of a novel 99mTc(CO)3-pyrazolyl conjugate of cyclo-(Arg-Gly-Asp-d-Tyr-Lys). , 2007, Bioconjugate chemistry.
[605] P. O'Connor. Natalizumab and the role of α4-integrin antagonism in the treatment of multiple sclerosis , 2007 .
[606] David C. Smith,et al. EMD121974 (NSC 707544, cilengitide) in asymptomatic metastatic androgen independent prostate cancer (AIPCa) patients (pts): A randomized trial by the Prostate Cancer Clinical Trials Consortium (NCI 6372) , 2007 .
[607] J. Folkman. Angiogenesis: an organizing principle for drug discovery? , 2007, Nature reviews. Drug discovery.
[608] W. Cai,et al. PET imaging of acute and chronic inflammation in living mice , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[609] Daniel L. Gustafson,et al. Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors , 2007 .
[610] A. Joussen,et al. The role of integrin α5β1 in the regulation of corneal neovascularization , 2007 .
[611] Sanjiv S. Gambhir,et al. Dual-Function Probe for PET and Near-Infrared Fluorescence Imaging of Tumor Vasculature , 2007, Journal of Nuclear Medicine.
[612] C. Rochlitz,et al. Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial , 2007, Clinical Cancer Research.
[613] E. Raymond,et al. Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors , 2008, Investigational New Drugs.
[614] G. Christofori,et al. Increased tumor cell dissemination and cellular senescence in the absence of β1‐integrin function , 2007, The EMBO journal.
[615] R. Stupp,et al. Integrin inhibitors reaching the clinic. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[616] K. Ataga,et al. Phase I study of eptifibatide in patients with sickle cell anaemia , 2007, British journal of haematology.
[617] S. Figueroa,et al. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues , 2007, Proceedings of the National Academy of Sciences.
[618] Xiaoyuan Chen,et al. 68Ga-labeled multimeric RGD peptides for microPET imaging of integrin αvβ3 expression , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[619] Anna Moore,et al. In vivo imaging of siRNA delivery and silencing in tumors , 2007, Nature Medicine.
[620] Xiaohu Gao,et al. Quantum dots for cancer molecular imaging. , 2009, Advances in experimental medicine and biology.
[621] Weibo Cai,et al. Nanoplatforms for targeted molecular imaging in living subjects. , 2007, Small.
[622] Freddy T. Nguyen,et al. Multimodal biomedical imaging with asymmetric single-walled carbon nanotube/iron oxide nanoparticle complexes. , 2007, Nano letters.
[623] D. Parker,et al. RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker ανβ3 integrin with MR T1 mapping , 2007, International journal of nanomedicine.
[624] P. Weinreb,et al. Structure-Function Analysis of Arg-Gly-Asp Helix Motifs in αvβ6 Integrin Ligands* , 2007, Journal of Biological Chemistry.
[625] A. Gorter,et al. Overexpression of the αvβ6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival , 2007 .
[626] J. Lindquist,et al. Cooperation between VEGF and beta3 integrin during cardiac vascular development. , 2007, Blood.
[627] Robert A. Beckman,et al. Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.
[628] Ralph Weissleder,et al. Multimodality Molecular Imaging Identifies Proteolytic and Osteogenic Activities in Early Aortic Valve Disease , 2007, Circulation.
[629] David Silverstein,et al. Growth factor binding to the pericellular matrix and its importance in tissue engineering. , 2007, Advanced drug delivery reviews.
[630] W. Cai,et al. microPET of Tumor Integrin αvβ3 Expression Using 18F-Labeled PEGylated Tetrameric RGD Peptide (18F-FPRGD4) , 2007, Journal of Nuclear Medicine.
[631] Markus Schwaiger,et al. [18F]Galacto-RGD Positron Emission Tomography for Imaging of αvβ3 Expression on the Neovasculature in Patients with Squamous Cell Carcinoma of the Head and Neck , 2007, Clinical Cancer Research.
[632] Benjamin R. Jarrett,et al. Core/shell quantum dots with high relaxivity and photoluminescence for multimodality imaging. , 2007, Journal of the American Chemical Society.
[633] Horst Kessler,et al. Design and chemical synthesis of integrin ligands. , 2007, Methods in enzymology.
[634] Wolfhard Semmler,et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. , 2007, Cancer research.
[635] C. Bode,et al. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists. , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[636] M. Gawaz,et al. Where is the trace? Molecular imaging of vulnerable atherosclerotic plaques. , 2007, Seminars in thrombosis and hemostasis.
[637] W. Cai,et al. 64Cu-Labeled Tetrameric and Octameric RGD Peptides for Small-Animal PET of Tumor αvβ3 Integrin Expression , 2007, Journal of Nuclear Medicine.
[638] F. Eskens,et al. Vascular disrupting agents in clinical development , 2007, British Journal of Cancer.
[639] J. Ying,et al. Synthesis of silica-coated semiconductor and magnetic quantum dots and their use in the imaging of live cells. , 2007, Angewandte Chemie.
[640] J. Rao,et al. Fluorescence imaging in vivo: recent advances. , 2007, Current opinion in biotechnology.
[641] Weibo Cai,et al. Semiconductor quantum dots for in vivo imaging. , 2007, Journal of nanoscience and nanotechnology.
[642] J. Sutcliffe,et al. Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. , 2007, Cancer research.
[643] Young-Seung Kim,et al. Evaluation of a 99mTc-Labeled Cyclic RGD Tetramer for Noninvasive Imaging Integrin αvβ3-Positive Breast Cancer , 2007 .
[644] J. Christensen,et al. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. , 2007, Neuro-oncology.
[645] A. Kolodkin,et al. Semaphorin 7A initiates T-cell-mediated inflammatory responses through α1β1 integrin , 2007, Nature.
[646] Arwin J. Brouwer,et al. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. , 2007, Organic & biomolecular chemistry.
[647] J. Takagi,et al. The RGD motif in fibronectin is essential for development but dispensable for fibril assembly , 2007, The Journal of cell biology.
[648] Samuel Achilefu,et al. In Vivo Resolution of Multiexponential Decays of Multiple Near-Infrared Molecular Probes by Fluorescence Lifetime-Gated Whole-Body Time-Resolved Diffuse Optical Imaging , 2007, Molecular imaging.
[649] M. Labinaz,et al. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention. , 2007, The Canadian journal of cardiology.
[650] P. Perriat,et al. Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. , 2007, Journal of the American Chemical Society.
[651] E. Krenning,et al. Octreoscan radioreceptor imaging , 2003, Endocrine.
[652] S. Targan,et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. , 2007, Gastroenterology.
[653] J. Panda,et al. The present and future of nanotechnology in human health care. , 2007, Nanomedicine : nanotechnology, biology, and medicine.
[654] H. Dai,et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. , 2020, Nature nanotechnology.
[655] Noriaki Ohuchi,et al. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. , 2007, Cancer research.
[656] R. Alon,et al. Integrin modulation and signaling in leukocyte adhesion and migration , 2007, Immunological reviews.
[657] C. Carman,et al. Structural basis of integrin regulation and signaling. , 2007, Annual review of immunology.
[658] Laura Crocetti,et al. Clinical management of focal liver lesions: the key role of real-time contrast-enhanced US , 2007, European radiology.
[659] F. Kruse,et al. Inhibition of Inflammatory Lymphangiogenesis by Integrin α5 Blockade , 2007 .
[660] S. Kuwada. Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. , 2007, Current opinion in molecular therapeutics.
[661] Ralph Weissleder,et al. Emerging concepts in molecular MRI. , 2007, Current opinion in biotechnology.
[662] E Grabbe,et al. In vivo imaging in experimental preclinical tumor research–A review , 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[663] Xiaojing Ye,et al. The integrins , 2007, Genome Biology.
[664] David H. Miller,et al. Health‐related quality of life in multiple sclerosis: effects of natalizumab , 2007, Annals of neurology.
[665] R. Liddington,et al. Structural Basis of Integrin Activation by Talin , 2007, Cell.
[666] M. Schwaiger,et al. Comparison of Integrin αvβ3 Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD and 18F-FDG , 2007, Journal of Nuclear Medicine.
[667] Zhuang Liu,et al. Carbon nanotubes as photoacoustic molecular imaging agents in living mice. , 2008, Nature nanotechnology.
[668] Ick Chan Kwon,et al. Activatable imaging probes with amplified fluorescent signals. , 2008, Chemical communications.
[669] Fan Wang,et al. Integrin αvβ3‐targeted cancer therapy , 2008 .
[670] Weibo Cai,et al. Multimodality Molecular Imaging of Tumor Angiogenesis , 2008, Journal of Nuclear Medicine.
[671] Klaas Nicolay,et al. Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging. , 2008, Bioconjugate chemistry.
[672] M. Brodmann,et al. 99mTc-apcitide scintigraphy in patients with clinically suspected deep venous thrombosis and pulmonary embolism , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[673] Ciprian Catana,et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging , 2008, Nature Medicine.
[674] Shuang Liu,et al. 99mTc-labeling of HYNIC-conjugated cyclic RGDfK dimer and tetramer using EDDA as coligand. , 2008, Bioconjugate chemistry.
[675] J. Tonn,et al. Expression of Integrin αvβ3 in Gliomas Correlates with Tumor Grade and Is not Restricted to Tumor Vasculature , 2008, Brain pathology.
[676] S. Nekolla,et al. In vivo molecular imaging of angiogenesis, targeting alphavbeta3 integrin expression, in a patient after acute myocardial infarction. , 2008, European heart journal.
[677] J. Waterton,et al. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast‐enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol) , 2008, NMR in biomedicine.
[678] Matthias Glaser,et al. Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients , 2008, Journal of Nuclear Medicine.
[679] E. Chavakis,et al. Del-1, an Endogenous Leukocyte-Endothelial Adhesion Inhibitor, Limits Inflammatory Cell Recruitment , 2008, Science.
[680] L. Tentori,et al. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma. , 2008, Oncology reports.
[681] W. Heindel,et al. Fluorescence Reflectance Imaging of Macrophage-Rich Atherosclerotic Plaques Using an αvβ3 Integrin–Targeted Fluorochrome , 2008, Journal of Nuclear Medicine.
[682] A. Hui,et al. The Biodistribution and Radiation Dosimetry of the Arg-Gly-Asp Peptide 18F-AH111585 in Healthy Volunteers , 2008, Journal of Nuclear Medicine.
[683] Sanjiv S Gambhir,et al. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. , 2008, Radiology.
[684] Z. Fayad,et al. Molecular imaging of tumor angiogenesis using αvβ3-integrin targeted multimodal quantum dots , 2008, Angiogenesis.
[685] John J. Young,et al. Abciximab: a review and update for clinicians , 2008, Expert review of cardiovascular therapy.
[686] T. Mikkelsen,et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. , 2008, Expert opinion on investigational drugs.
[687] Xiaoyuan Chen,et al. Advances in Anatomic, Functional, and Molecular Imaging of Angiogenesis , 2008, Journal of Nuclear Medicine.
[688] Young-Seung Kim,et al. Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. , 2008, Journal of medicinal chemistry.
[689] C. Bokemeyer,et al. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway , 2008, Journal of experimental & clinical cancer research : CR.
[690] Eric Pridgen,et al. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.
[691] Bernd J Pichler,et al. Radionuclide imaging: a molecular key to the atherosclerotic plaque. , 2008, Journal of the American College of Cardiology.
[692] M. Scully,et al. The Role of Integrins in Cancer and the Development of Anti-Integrin Therapeutic Agents for Cancer Therapy , 2008, Perspectives in medicinal chemistry.
[693] Wolfhard Semmler,et al. Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects , 2008, Molecular Cancer Therapeutics.
[694] Klaas Nicolay,et al. Improved magnetic resonance molecular imaging of tumor angiogenesis by avidin-induced clearance of nonbound bimodal liposomes. , 2008, Neoplasia.
[695] Weibo Cai,et al. Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging , 2008, Nature Protocols.
[696] S. Rigby,et al. Engineering silica particles as oral drug delivery vehicles. , 2008, Current pharmaceutical design.
[697] Orazio Schillaci,et al. Molecular imaging of atheroslerotic plaque with nuclear medicine techniques. , 2008, International journal of molecular medicine.
[698] H. Maecke,et al. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. , 2008, Contrast media & molecular imaging.
[699] Robert Sinclair,et al. Real-time intravital imaging of RGD-quantum dot binding to luminal endothelium in mouse tumor neovasculature. , 2008, Nano letters.
[700] B. Garmy-Susini,et al. Integrins in angiogenesis and lymphangiogenesis , 2008, Nature Reviews Cancer.
[701] T. Springer,et al. An unusual allosteric mobility of the C-terminal helix of a high-affinity alphaL integrin I domain variant bound to ICAM-5. , 2008, Molecular cell.
[702] Chenjie Xu,et al. PET/MRI Dual-Modality Tumor Imaging Using Arginine-Glycine-Aspartic (RGD)–Conjugated Radiolabeled Iron Oxide Nanoparticles , 2008, Journal of Nuclear Medicine.
[703] Kathryn E. Luker,et al. Optical Imaging: Current Applications and Future Directions , 2007, Journal of Nuclear Medicine.
[704] Fan Wang,et al. Linker effects on biological properties of 111In-labeled DTPA conjugates of a cyclic RGDfK dimer. , 2008, Bioconjugate chemistry.
[705] S. Danese,et al. Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go. , 2008, Autoimmunity reviews.
[706] Kit S. Lam,et al. In vivo optical imaging of human lymphoma xenograft using a library-derived peptidomimetic against α4β1 integrin , 2008, Molecular Cancer Therapeutics.
[707] A. Cohen,et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[708] Ralph Weissleder,et al. Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis , 2008, Circulation.
[709] B. Coller,et al. Application of high-throughput screening to identify a novel alphaIIb-specific small- molecule inhibitor of alphaIIbbeta3-mediated platelet interaction with fibrinogen. , 2008, Blood.
[710] Fan Wang,et al. Integrin αvβ3-Targeted Radioimmunotherapy of Glioblastoma Multiforme , 2008, Clinical Cancer Research.
[711] Markus Schwaiger,et al. Imaging of integrin αvβ3 expression , 2008, Cancer and Metastasis Reviews.
[712] Fan Wang,et al. 68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin αvβ3 PET imaging , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[713] E. Moriyama,et al. Optical Molecular Imaging: From Single Cell to Patient , 2008, Clinical pharmacology and therapy.
[714] W. Cai,et al. Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein , 2008, Molecular Cancer Therapeutics.
[715] Daniel B. Martin,et al. Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.
[716] B. Hemmer,et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. , 2008, Archives of neurology.
[717] Ick Chan Kwon,et al. Dark quenched matrix metalloproteinase fluorogenic probe for imaging osteoarthritis development in vivo. , 2008, Bioconjugate chemistry.
[718] B. Pitt,et al. Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. , 2008, Journal of the American College of Cardiology.
[719] Shuang Liu,et al. Coligand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramer. , 2008, Nuclear medicine and biology.
[720] K. Lam,et al. Near-infrared optical imaging in glioblastoma xenograft with ligand-targeting α3 integrin , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[721] A. Tolcher,et al. Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study , 2008, Clinical Cancer Research.
[722] Nadia Harbeck,et al. Patterns of αvβ3 Expression in Primary and Metastatic Human Breast Cancer as Shown by 18F-Galacto-RGD PET , 2008, Journal of Nuclear Medicine.
[723] B. Furie,et al. Mechanisms of thrombus formation. , 2008, The New England journal of medicine.
[724] R. Weissleder,et al. Imaging in the era of molecular oncology , 2008, Nature.
[725] S. Gambhir,et al. Noninvasive Raman spectroscopy in living mice for evaluation of tumor targeting with carbon nanotubes. , 2008, Nano letters.
[726] N. Neamati,et al. Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide–paclitaxel conjugate in mice with breast cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[727] Weibo Cai,et al. Imaging of integrins as biomarkers for tumor angiogenesis. , 2008, Current pharmaceutical design.
[728] I. Campbell,et al. Transmembrane and cytoplasmic domains in integrin activation and protein-protein interactions (Review) , 2008, Molecular membrane biology.
[729] Cheuk Y. Tang,et al. Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. , 2008, Nano letters.
[730] Ian Walker,et al. In vivo and in vitro characterisation of a protoporphyrin IX-cyclic RGD peptide conjugate for use in photodynamic therapy , 2008, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.
[731] T. Mikkelsen,et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[732] T. MacDonald,et al. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[733] N. Shikano,et al. αvβ3 Integrin‐targeting radionuclide therapy and imaging with monomeric RGD peptide , 2008, International journal of cancer.
[734] Xiaoyuan Chen,et al. Has Molecular and Cellular Imaging Enhanced Drug Discovery and Drug Development? , 2008, Drugs in R&D.
[735] T. Yankeelov,et al. (cid:1) 2 (cid:2) 1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell–specific manner , 2022 .
[736] K. Lam,et al. Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method. , 2009, Journal of medicinal chemistry.
[737] Young-Seung Kim,et al. Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers. , 2009, Molecular pharmaceutics.
[738] S. Caruthers,et al. High Sensitivity: High-Resolution SPECT-CT/MR Molecular Imaging of Angiogenesis in the Vx2 Model , 2009, Investigative radiology.
[739] Zahi A Fayad,et al. Nanotechnology in Medical Imaging: Probe Design and Applications , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[740] T. Byzova,et al. Cooperation between integrin ανβ3 and VEGFR2 in angiogenesis , 2009, Angiogenesis.
[741] Ralph Weissleder,et al. Hybrid In Vivo FMT-CT Imaging of Protease Activity in Atherosclerosis With Customized Nanosensors , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[742] P. Billings,et al. The structure and function of platelet integrins , 2009, Journal of thrombosis and haemostasis : JTH.
[743] R. Nagler. Saliva as a tool for oral cancer diagnosis and prognosis. , 2009, Oral oncology.
[744] E. Major,et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. , 2009, The New England journal of medicine.
[745] C. Pozzilli,et al. Natalizumab treatment in pediatric multiple sclerosis: a case report. , 2009, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[746] Stephen L. Brown,et al. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule‐dependency , 2009, International journal of cancer.
[747] M. Humphries,et al. Anti-integrin monoclonal antibodies , 2009, Journal of Cell Science.
[748] I. van der Waal,et al. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. , 2009, Oral oncology.
[749] K. Lam,et al. 111In-LLP2A-DOTA Polyethylene Glycol–Targeting α4β1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies , 2009, Journal of Nuclear Medicine.
[750] H. Wester,et al. Molecular imaging targeting peptide receptors. , 2009, Methods.
[751] M. Conaway,et al. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. , 2009, Cancer research.
[752] Erkki Ruoslahti,et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. , 2009, Cancer cell.
[753] R. Erbel,et al. Coronary microembolization: from bedside to bench and back to bedside. , 2009, Circulation.
[754] J. Norman,et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors , 2009, Nature Medicine.
[755] H. Kessler,et al. Ligands for Mapping a v 3 -Integrin Expression in Vivo , 2009 .
[756] Samuel Achilefu,et al. Complementary optical and nuclear imaging of caspase-3 activity using combined activatable and radio-labeled multimodality molecular probe. , 2009, Journal of biomedical optics.
[757] Michael Scholz,et al. Molecular ultrasound imaging of early vascular response in prostate tumors irradiated with carbon ions. , 2009, Neoplasia.
[758] D. Miller,et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy , 2009, Neurology.
[759] F. Kiessling,et al. Functional and molecular ultrasound imaging: concepts and contrast agents. , 2009, Current medicinal chemistry.
[760] R. Kimura,et al. Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low‐nanomolar affinity , 2009, Proteins.
[761] Emily A. Smith,et al. Identifying cytoplasmic proteins that affect receptor clustering using fluorescence resonance energy transfer and RNA interference , 2009, Analytical and bioanalytical chemistry.
[762] S. Achilefu,et al. Multimodal Imaging of Integrin Receptor-Positive Tumors by Bioluminescence, Fluorescence, Gamma Scintigraphy, and Single-Photon Emission Computed Tomography Using a Cyclic RGD Peptide Labeled with a Near-Infrared Fluorescent Dye and a Radionuclide , 2009, Molecular imaging.
[763] C. Polman,et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study , 2009, The Lancet Neurology.
[764] Hisataka Kobayashi,et al. Clinical implications of near-infrared fluorescence imaging in cancer. , 2009, Future oncology.
[765] Jean Tessier,et al. Use of a Novel Arg-Gly-Asp Radioligand, 18F-AH111585, to Determine Changes in Tumor Vascularity After Antitumor Therapy , 2008, Journal of Nuclear Medicine.
[766] Fan Wang,et al. 99mTcO(MAG2-3G3-dimer): a new integrin αvβ3-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[767] R. Pettigrew,et al. High-Affinity αvβ3 Integrin Targeted Optical Probe as a New Imaging Biomarker for Early Atherosclerosis: Initial Studies in Watanabe Rabbits , 2009, Molecular Imaging and Biology.
[768] C. Tung,et al. Proteolysis: a biological process adapted in drug delivery, therapy, and imaging. , 2009, Bioconjugate chemistry.
[769] Kang-Choon Lee,et al. Emerging PEGylated drugs , 2009, Expert opinion on emerging drugs.
[770] Fan Wang,et al. Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers , 2011, Amino Acids.
[771] A. Pozzi,et al. Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. , 2009, Cancer research.
[772] David Piwnica-Worms,et al. Single-cell imaging of retinal ganglion cell apoptosis with a cell-penetrating, activatable peptide probe in an in vivo glaucoma model , 2009, Proceedings of the National Academy of Sciences.
[773] Xiaoyuan Chen,et al. Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. , 2009, Biomaterials.
[774] D. M. Foster,et al. Integrins and proximal signaling mechanisms in cardiovascular disease. , 2009, Frontiers in bioscience.
[775] Fan Wang,et al. Potential therapeutic radiotracers: preparation, biodistribution and metabolic characteristics of 177Lu-labeled cyclic RGDfK dimer , 2010, Amino Acids.
[776] G. Schultz,et al. Interactions between extracellular matrix and growth factors in wound healing , 2009, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.
[777] A. Berman,et al. Integrin α5β1 controls invasion of human breast carcinoma cells by direct and indirect modulation of MMP-2 collagenase activity , 2009 .
[778] Xiaoyuan Chen,et al. Small-Animal PET of Tumors with 64Cu-Labeled RGD-Bombesin Heterodimer , 2009, Journal of Nuclear Medicine.
[779] T. LaFramboise,et al. Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances , 2009, Nucleic acids research.
[780] G. Shopp,et al. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. , 2009, Birth defects research. Part B, Developmental and reproductive toxicology.
[781] L. Stead,et al. Evidence-based emergency medicine/systematic review abstract. Role of abciximab in the management of acute ischemic stroke. , 2009, Annals of emergency medicine.
[782] Kai Chen,et al. 18F-Labeled Galacto and PEGylated RGD Dimers for PET Imaging of αvβ3 Integrin Expression , 2010, Molecular Imaging and Biology.
[783] Silvia Marchesan,et al. Regulation of integrin activity and signalling. , 2009, Biochimica et biophysica acta.
[784] D. Clifford,et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. , 2009, The New England journal of medicine.
[785] S. Gambhir,et al. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. , 2009, Cancer research.
[786] S. Rahman. Deep vein thrombosis prophylaxis: friend or foe. , 2009, American journal of therapeutics.
[787] 2-Mercaptoacetylglycylglycyl (MAG2) as a bifunctional chelator for 99mTc-labeling of cyclic RGD dimers: effect of technetium chelate on tumor uptake and pharmacokinetics. , 2009, Bioconjugate chemistry.
[788] C. Ahn,et al. Polymeric nanoparticle-based activatable near-infrared nanosensor for protease determination in vivo. , 2009, Nano letters.
[789] Young-Seung Kim,et al. Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. , 2009, Bioconjugate chemistry.
[790] J. Norman,et al. Integrins: masters and slaves of endocytic transport , 2009, Nature Reviews Molecular Cell Biology.
[791] P. Mischel,et al. Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. , 2009, Cancer research.
[792] S. Achilefu,et al. In vivo fluorescence lifetime tomography. , 2009, Journal of biomedical optics.
[793] H. Hong,et al. Molecular Imaging with Single-Walled Carbon Nanotubes. , 2009, Nano today.
[794] R. Ransohoff,et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function , 2009, Neurology.
[795] R. Fässler,et al. Genetic and cell biological analysis of integrin outside-in signaling. , 2009, Genes & development.
[796] B. Felding-Habermann,et al. Activation of tumor cell integrin αvβ3 controls angiogenesis and metastatic growth in the brain , 2009, Proceedings of the National Academy of Sciences.
[797] H. Kessler,et al. Ligands for mapping alphavbeta3-integrin expression in vivo. , 2009, Accounts of chemical research.
[798] Fan Wang,et al. Noninvasive imaging of tumor integrin expression using 18F-labeled RGD dimer peptide with PEG4 linkers , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[799] Sven H. Hausner,et al. Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model. , 2009, Cancer research.
[800] G. Shopp,et al. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. , 2009, Birth defects research. Part B, Developmental and reproductive toxicology.
[801] S. Gambhir,et al. An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. , 2009, Bioconjugate chemistry.
[802] Fan Wang,et al. Tumor uptake of the RGD dimeric probe (99m)Tc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature. , 2010, Bioconjugate chemistry.
[803] Seulki Lee,et al. Activatable molecular probes for cancer imaging. , 2010, Current topics in medicinal chemistry.
[804] Adam P. Silverman,et al. Evaluation of a 64Cu-Labeled Cystine-Knot Peptide Based on Agouti-Related Protein for PET of Tumors Expressing αvβ3 Integrin , 2010, Journal of Nuclear Medicine.
[805] Z. Werb,et al. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.
[806] K. Uzawa,et al. MicroRNAs in Head and Neck Squamous Cell Carcinoma (HNSCC) and Oral Squamous Cell Carcinoma (OSCC) , 2010, Cancers.
[807] S. Gambhir,et al. PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide. , 2010, Cancer research.
[808] Xiaoyuan Chen,et al. Optical imaging of integrin alphavbeta3 expression with near-infrared fluorescent RGD dimer with tetra(ethylene glycol) linkers. , 2010, Molecular imaging.
[809] Miriam Scadeng,et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival , 2010, Proceedings of the National Academy of Sciences.
[810] K. Belfield,et al. Linear and nonlinear photophysics and bioimaging of an integrin-targeting water-soluble fluorenyl probe. , 2010, Organic & biomolecular chemistry.
[811] Ernst J. Rummeny,et al. Phenotyping of Tumor Biology in Patients by Multimodality Multiparametric Imaging: Relationship of Microcirculation, αvβ3 Expression, and Glucose Metabolism , 2010, The Journal of Nuclear Medicine.
[812] Fan Wang,et al. Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent. , 2010, Bioconjugate chemistry.
[813] David A. Cheresh,et al. Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.
[814] Albert J. Sinusas,et al. PET and SPECT in cardiovascular molecular imaging , 2010, Nature Reviews Cardiology.
[815] Y. Fujibayashi,et al. Effect of multimerization of a linear Arg-Gly-Asp peptide on integrin binding affinity and specificity. , 2010, Biological & pharmaceutical bulletin.
[816] M. Schwaiger,et al. Molecular imaging of αvß3 expression in cancer patients. , 2010, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[817] I. Waal. Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management , 2010 .
[818] Fan Wang,et al. Optical Imaging of Integrin αvβ3 Expression with Near-Infrared Fluorescent RGD Dimer with Tetra(ethylene glycol) Linkers , 2010 .
[819] R. Kimura,et al. Preliminary evaluation of 177Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[820] G. Mező,et al. Receptor-mediated tumor targeting based on peptide hormones , 2010, Expert opinion on drug delivery.
[821] S. Gambhir,et al. A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects. , 2010, Bioconjugate chemistry.
[822] Seulki Lee,et al. Peptides and peptide hormones for molecular imaging and disease diagnosis. , 2010, Chemical reviews.
[823] R. Tsien. The 2009 Lindau Nobel Laureate Meeting: Roger Y. Tsien, Chemistry 2008. , 2010, Journal of visualized experiments : JoVE.
[824] Seulki Lee,et al. Peptide-based probes for targeted molecular imaging. , 2010, Biochemistry.
[825] M. Gordon. A Randomized Phase 2 Study of Etaracizumab, a Monoclonal Antibody Against Integrin αvβ3, ± Dacarbazine in Patients With Stage IV Metastatic Melanoma , 2011 .
[826] Peter Beyerlein,et al. Diagnostic potential of saliva: current state and future applications. , 2011, Clinical chemistry.
[827] Fan Zhang,et al. Chimeric ferritin nanocages for multiple function loading and multimodal imaging. , 2011, Nano letters.
[828] K. Kostner,et al. One-step homogeneous C-reactive protein assay for saliva. , 2011, Journal of immunological methods.
[829] Wei Wu. MicroRNA and Cancer , 2011, Methods in Molecular Biology.
[830] R. Greer. Oral manifestations of smokeless tobacco use. , 2011, Otolaryngologic clinics of North America.
[831] Ralph Weissleder,et al. Molecular optical imaging: Applications leading to the development of present day therapeutics , 2005, NeuroRX.
[832] K. Kostner,et al. NT-ProBNP Levels in Saliva and Its Clinical Relevance to Heart Failure , 2012, PloS one.
[833] J. Alexander,et al. Recent Antiplatelet Drug Trials in the Acute Coronary Syndromes , 1998, Drugs.
[834] R. Sharan,et al. Association of Betel Nut with Carcinogenesis: Revisit with a Clinical Perspective , 2012, PloS one.
[835] C. Punyadeera,et al. miRNAs in head and neck cancer revisited , 2013, Cellular Oncology.
[836] C. Bock. Analysing and interpreting DNA methylation data , 2012, Nature Reviews Genetics.
[837] A. Guimaraes,et al. Molecular Imaging of Tumor Angiogenesis , 2012 .
[838] G. Dimeski,et al. The impact of saliva collection and processing methods on CRP, IgE, and Myoglobin immunoassays , 2012, Clinical and Translational Medicine.
[839] J. Becker,et al. Suppression of p53 Activity and p21 WAF1/CIP1 Expression by Vascular Cell Integrin during Angiogenesis , 1996 .
[840] Cynthia,et al. Involvement of Integrin aV Gene Expression in Human Melanoma Tumorigenicity , 2003 .
[841] D. Messadi,et al. Diagnostic aids for detection of oral precancerous conditions , 2013, International Journal of Oral Science.
[842] C. Wiener. Harrison's principles of internal medicine , 2013 .
[843] D. Cheresh,et al. Human Melanoma Cells Derived from Lymphatic Metastases Use Integrin aCv3 to Adhere to Lymph Node Vitronectin , 2013 .
[844] Diego A. Calvopina,et al. miRNAs in human papilloma virus associated oral and oropharyngeal squamous cell carcinomas , 2014, Expert review of molecular diagnostics.
[845] H. Wood,et al. MicroRNAs and head and neck cancer: reviewing the first decade of research. , 2014, European Journal of Cancer.
[846] John M. Wright,et al. A review of research on salivary biomarkers for oral cancer detection , 2014, Clinical and Translational Medicine.
[847] Michaell A. Huber,et al. Oral and oropharyngeal cancer. , 2014, The Medical clinics of North America.
[848] R. Gregory,et al. MicroRNA biogenesis pathways in cancer , 2015, Nature Reviews Cancer.
[849] C. Scully,et al. Salivary microRNAs in oral cancer. , 2015, Oral diseases.
[850] Melissa J. Davis,et al. Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers , 2016, BMC Cancer.
[851] Yong Peng,et al. The role of MicroRNAs in human cancer , 2016, Signal Transduction and Targeted Therapy.
[852] P. Low,et al. Receptor-Mediated Drug Delivery , 2016 .
[853] K. Kostner,et al. Saliva: Linking oral health with heart failure , 2017 .
[854] S. Calza,et al. Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer , 2017, The Laryngoscope.
[855] I. Frazer,et al. The overexpression of salivary cytokeratins as potential diagnostic biomarkers in head and neck squamous cell carcinomas , 2017, Oncotarget.
[856] D. Vagenas,et al. Salivary miRNA panel to detect HPV-positive and HPV-negative head and neck cancer patients , 2017, Oncotarget.
[857] B. Sullenger,et al. Tunable cytotoxic aptamer–drug conjugates for the treatment of prostate cancer , 2018, Proceedings of the National Academy of Sciences.
[858] R. Hynes,et al. Embryonic mesodermal defects in 5 integrin-deficient mice , 1996 .